Characterization	O
of	O
interleukin-10	B-protein
receptor	I-protein
expression	O
on	O
B-cell	B-cell_line
chronic	I-cell_line
lymphocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

B-cell	B-cell_line
chronic	I-cell_line
lymphocytic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
B-CLL	I-cell_line
)	I-cell_line
cells	I-cell_line
accumulate	O
in	O
vivo	O
in	O
the	O
G0/G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
suggesting	O
that	O
their	O
malignant	O
expansion	O
is	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
delay	O
in	O
cell	O
death	O
.	O

However	O
,	O
the	O
cellular	O
or	O
molecular	B-protein
factors	I-protein
responsible	O
for	O
a	O
delay	O
in	O
B-CLL	O
cell	O
death	O
are	O
unknown	O
.	O

B-CLL	O
cells	O
do	O
express	O
receptors	O
for	O
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
and	O
IFN-gamma	B-protein
,	O
and	O
activation	O
of	O
both	O
has	O
been	O
shown	O
to	O
promote	O
B-CLL	O
survival	O
in	O
vitro	O
by	O
preventing	O
apoptosis	O
.	O

The	O
interleukin-10	B-protein
(	I-protein
IL-10	I-protein
)	I-protein
receptor	I-protein
is	O
another	O
member	O
of	O
the	O
IFN	B-protein
receptor	I-protein
family	I-protein
,	O
but	O
its	O
ligand	O
,	O
IL-10	B-protein
,	O
has	O
been	O
reported	O
to	O
induce	O
apoptosis	O
in	O
B-CLL	B-cell_line
cells	I-cell_line
.	O

In	O
the	O
current	O
study	O
,	O
we	O
undertook	O
a	O
biochemical	O
analysis	O
of	O
IL-10	B-protein
receptor	I-protein
expression	O
on	O
freshly	O
isolated	O
B-CLL	B-cell_line
cells	I-cell_line
and	O
characterized	O
the	O
functional	O
responsiveness	O
of	O
IL-10	B-protein
binding	O
to	O
its	O
constitutively	B-protein
expressed	I-protein
receptor	I-protein
.	O

We	O
show	O
that	O
B-CLL	B-cell_line
cells	I-cell_line
bind	O
IL-10	B-protein
with	O
significant	O
specificity	O
and	O
express	O
between	O
47	O
and	O
127	O
IL-10	B-protein
receptor	I-protein
sites	O
per	O
cell	O
,	O
with	O
a	O
dissociation	O
constant	O
in	O
the	O
range	O
of	O
168	O
to	O
426	O
x	O
10	O
(	O
-12	O
)	O
mol/L	O
.	O

Ligand	O
binding	O
and	O
activation	O
of	O
the	O
IL-10	B-protein
receptor	I-protein
expressed	O
on	O
B-CLL	B-cell_line
cells	I-cell_line
results	O
in	O
the	O
phosphorylation	O
of	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
1	I-protein
(	O
STAT1	B-protein
)	O
and	O
STAT3	B-protein
proteins	O
.	O

This	O
pattern	O
of	O
STAT	B-protein
protein	I-protein
phosphorylation	O
is	O
identical	O
to	O
IL-10	B-protein
receptor	I-protein
activation	O
on	O
normal	B-cell_type
cells	I-cell_type
and	O
similar	O
to	O
IFN-alpha	B-protein
(	O
STAT1	B-protein
and	O
STAT3	B-protein
)	O
and	O
IFN-gamma	B-protein
(	O
STAT1	B-protein
)	O
receptor	O
activation	O
in	O
CLL	B-cell_line
.	O

Further	O
,	O
in	O
consecutive	O
samples	O
of	O
fresh	O
blood	O
obtained	O
from	O
patients	O
with	O
B-CLL	B-cell_line
cells	I-cell_line
,	O
the	O
addition	O
of	O
IL-10	B-protein
inhibited	O
B-CLL	B-cell_line
proliferation	O
,	O
enhanced	O
B-CLL	B-cell_line
differentiation	O
,	O
but	O
did	O
not	O
induce	O
apoptosis	O
.	O

Indeed	O
,	O
IL-10	B-protein
,	O
like	O
IFN-gamma	B-protein
,	O
was	O
able	O
to	O
significantly	O
reduce	O
the	O
amount	O
of	O
B-CLL	O
cell	O
death	O
caused	O
by	O
hydrocortisone-induced	O
apoptosis	O
.	O

We	O
conclude	O
that	O
cytokines	B-protein
,	O
which	O
signal	O
through	O
the	O
interferon	B-protein
family	I-protein
of	O
receptors	O
,	O
have	O
comparable	O
functional	O
effects	O
on	O
B-CLL	B-cell_line
cells	I-cell_line
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Characterization	NULL
of	NULL
Interleukin-10	NULL
Receptor	NULL
Expression	NULL
on	NULL
B-Cell	NULL
Chronic	NULL
Lymphocytic	NULL
Leukemia	NULL
Cells	NULL
By	NULL
Jesper	NULL
Jurlander	NULL
,	NULL
Chun-Fai	NULL
Lai	NULL
,	NULL
Jimmy	NULL
Tan	NULL
,	NULL
Chuan-Chu	NULL
Chou	NULL
,	NULL
Christian	NULL
H.	NULL
Geisler	NULL
,	NULL
Jeffrey	NULL
Schriber	NULL
,	NULL
Leslie	NULL
E.	NULL
Blumenson	NULL
,	NULL
Satwant	NULL
K.	NULL
Narula	NULL
,	NULL
Heinz	NULL
Baumann	NULL
,	NULL
and	NULL
Michael	NULL
A.	NULL
Caligiuri	NULL
B-cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
(	NULL
B-CLL	NULL
)	NULL
cells	NULL
accumulate	NULL
in	NULL
vivo	NULL
in	NULL
the	NULL
G	NULL
,	NULL
/G	NULL
,	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
suggesting	NULL
that	NULL
their	NULL
malignant	NULL
expansion	NULL
is	NULL
due	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
to	NULL
a	NULL
delay	NULL
in	NULL
cell	NULL
death	NULL
.	NULL

However	NULL
,	NULL
the	NULL
cellular	NULL
or	NULL
molecular	NULL
factors	NULL
responsible	NULL
for	NULL
a	NULL
delay	NULL
in	NULL
B-CLL	NULL
cell	NULL
death	NULL
are	NULL
unknown	NULL
.	NULL

B-CLL	NULL
cells	NULL
do	NULL
express	NULL
receptors	NULL
for	NULL
interferon-a	NULL
(	NULL
IFN-a	NULL
)	NULL
and	NULL
IFN-y	NULL
,	NULL
and	NULL
activation	NULL
of	NULL
both	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
promote	NULL
B-CLL	NULL
survival	NULL
in	NULL
vitro	NULL
by	NULL
preventing	NULL
apoptosis	NULL
.	NULL

The	NULL
interleukin-10	NULL
(	NULL
IL-10	NULL
}	NULL
receptor	NULL
is	NULL
another	NULL
member	NULL
of	NULL
the	NULL
IFN	NULL
receptor	NULL
family	NULL
,	NULL
but	NULL
its	NULL
ligand	NULL
,	NULL
IL-10	NULL
,	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
induce	NULL
apoptosis	NULL
in	NULL
B-CLL	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
current	NULL
study	NULL
,	NULL
we	NULL
undertook	NULL
a	NULL
biochemical	NULL
analysis	NULL
of	NULL
IL-10	NULL
receptor	NULL
expression	NULL
on	NULL
freshly	NULL
isolated	NULL
B-CLL	NULL
cells	NULL
and	NULL
characterized	NULL
the	NULL
functional	NULL
responsiveness	NULL
of	NULL
IL-10	NULL
binding	NULL
to	NULL
its	NULL
constitutively	NULL
expressed	NULL
receptor	NULL
.	NULL

We	NULL
show	NULL
that	NULL
B-CLL	NULL
cells	NULL
bind	NULL
IL-10	NULL
with	NULL
significant	NULL
specificity	NULL
and	NULL
express	NULL
between	NULL
47	NULL
and	NULL
127	NULL
IL-10	NULL
receptor	NULL
sites	NULL
per	NULL
cell	NULL
,	NULL
with	NULL
a	NULL
dissociation	NULL
constant	NULL
in	NULL
the	NULL
ORMAL	NULL
TISSUE	NULL
homeostasis	NULL
requires	NULL
constant	NULL
regulation	NULL
of	NULL
cell	NULL
growth	NULL
and	NULL
cell	NULL
death	NULL
.	NULL
``	NULL

In	NULL
B-cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
(	NULL
B-CLL	NULL
)	NULL
,	NULL
the	NULL
malignant	NULL
cells	NULL
are	NULL
arrested	NULL
in	NULL
the	NULL
G	NULL
,	NULL
/G	NULL
,	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Accumulation	NULL
of	NULL
immunologically	NULL
incompetent	NULL
B-CLL	NULL
cells	NULL
in	NULL
vivo	NULL
is	NULL
therefore	NULL
thought	NULL
to	NULL
result	NULL
more	NULL
from	NULL
a	NULL
delay	NULL
in	NULL
cell	NULL
death	NULL
rather	NULL
than	NULL
an	NULL
increase	NULL
in	NULL
cell	NULL
growth	NULL
.	NULL
``	NULL

''	NULL
The	NULL
cause	NULL
of	NULL
this	NULL
delay	NULL
in	NULL
cell	NULL
death	NULL
is	NULL
not	NULL
known	NULL
,	NULL
but	NULL
may	NULL
involve	NULL
an	NULL
imbalance	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
gene	NULL
products	NULL
that	NULL
control	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL
``	NULL

''	NULL
However	NULL
,	NULL
specific	NULL
serologic	NULL
factors	NULL
or	NULL
consistent	NULL
genetic	NULL
defects	NULL
responsible	NULL
for	NULL
such	NULL
imbalances	NULL
in	NULL
gene	NULL
expression	NULL
in	NULL
vivo	NULL
have	NULL
not	NULL
been	NULL
identified	NULL
in	NULL
B-CLL	NULL
.	NULL

In	NULL
vitro	NULL
culture	NULL
of	NULL
B-CLL	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
human	NULL
serum	NULL
leads	NULL
to	NULL
a	NULL
gradual	NULL
decrease	NULL
in	NULL
bel-2	NULL
expression	NULL
and	NULL
induction	NULL
of	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL
``	NULL

''	NULL
This	NULL
process	NULL
can	NULL
be	NULL
delayed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
certain	NULL
cytokines	NULL
such	NULL
as	NULL
interleukin-4	NULL
(	NULL
IL-4	NULL
)	NULL
,	NULL
IL-13	NULL
,	NULL
interferon-a	NULL
(	NULL
IFN-	NULL
@	NULL
)	NULL
,	NULL
and	NULL
IFN-y	NULL
.	NULL
``	NULL

From	NULL
the	NULL
Division	NULL
of	NULL
Medicine	NULL
,	NULL
the	NULL
Department	NULL
of	NULL
Molecular	NULL
and	NULL
Cell	NULL
Biology	NULL
,	NULL
Roswell	NULL
Park	NULL
Cancer	NULL
Institute	NULL
,	NULL
Buffalo	NULL
,	NULL
NY	NULL
;	NULL
the	NULL
Department	NULL
of	NULL
Hematology	NULL
,	NULL
The	NULL
Finsencenter	NULL
,	NULL
Rigshospitalet	NULL
,	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
;	NULL
and	NULL
Schering	NULL
Plough	NULL
Research	NULL
Institute	NULL
,	NULL
Kenilworth	NULL
,	NULL
NJ	NULL
.	NULL

Submitted	NULL
May	NULL
30	NULL
,	NULL
1996	NULL
;	NULL
accepted	NULL
December	NULL
20	NULL
,	NULL
1996	NULL
.	NULL

Supported	NULL
by	NULL
the	NULL
Danish	NULL
Medical	NULL
Research	NULL
Council	NULL
(	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
)	NULL
,	NULL
the	NULL
Danish	NULL
Cancer	NULL
Society	NULL
(	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
)	NULL
,	NULL
The	NULL
Elizabeth	NULL
and	NULL
Carl-Ejnar	NULL
Nis-Hansen	NULL
Foundation	NULL
(	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
)	NULL
,	NULL
The	NULL
John	NULL
and	NULL
Birthe	NULL
Meyer	NULL
Foundation	NULL
(	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
)	NULL
,	NULL
The	NULL
Spies	NULL
Foundation	NULL
(	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
)	NULL
,	NULL
The	NULL
Coleman	NULL
Leukemia	NULL
Research	NULL
Foundation	NULL
(	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
,	NULL
and	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
No	NULL
.	NULL

CA26122	NULL
,	NULL
DK33886	NULL
,	NULL
CA65670	NULL
,	NULL
and	NULL
CA68458	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Michael	NULL
A.	NULL
Caligiuri	NULL
,	NULL
MD	NULL
,	NULL
Division	NULL
of	NULL
Medicine	NULL
,	NULL
Roswell	NULL
Park	NULL
Cancer	NULL
Institute	NULL
,	NULL
Buffalo	NULL
,	NULL
NY	NULL
14263	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1997	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/97/8911-0028	NULL
$	NULL
3.00/0	NULL
4146	NULL
range	NULL
of	NULL
168	NULL
to	NULL
426	NULL
x	NULL
10~	NULL
``	NULL
mol/L	NULL
.	NULL

Ligand	NULL
binding	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
IL-10	NULL
receptor	NULL
expressed	NULL
on	NULL
B-CLL	NULL
cells	NULL
results	NULL
in	NULL
the	NULL
phosphorylation	NULL
of	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
1	NULL
(	NULL
STAT1	NULL
)	NULL
and	NULL
STAT3	NULL
proteins	NULL
.	NULL

This	NULL
pattern	NULL
of	NULL
STAT	NULL
protein	NULL
phosphorylation	NULL
is	NULL
identical	NULL
to	NULL
IL-10	NULL
receptor	NULL
activation	NULL
on	NULL
normal	NULL
cells	NULL
and	NULL
similar	NULL
to	NULL
IFN-a	NULL
(	NULL
STAT1	NULL
and	NULL
STAT3	NULL
)	NULL
and	NULL
IFN-y	NULL
(	NULL
STAT1	NULL
)	NULL
receptor	NULL
activation	NULL
in	NULL
CLL	NULL
.	NULL

Fur-ther	NULL
,	NULL
in	NULL
consecutive	NULL
samples	NULL
of	NULL
fresh	NULL
blood	NULL
obtained	NULL
from	NULL
patients	NULL
with	NULL
B-CLL	NULL
cells	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
IL-10	NULL
inhibited	NULL
B-CLL	NULL
proliferation	NULL
,	NULL
enhanced	NULL
B-CLL	NULL
differentiation	NULL
,	NULL
but	NULL
did	NULL
not	NULL
induce	NULL
apoptosis	NULL
.	NULL

Indeed	NULL
,	NULL
IL-10	NULL
,	NULL
like	NULL
IFN-y	NULL
,	NULL
was	NULL
able	NULL
to	NULL
significantly	NULL
reduce	NULL
the	NULL
amount	NULL
of	NULL
B-CLL	NULL
cell	NULL
death	NULL
caused	NULL
by	NULL
hydrocortisone-induced	NULL
apoptosis	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
cy-tokines	NULL
,	NULL
which	NULL
signal	NULL
through	NULL
the	NULL
interferon	NULL
family	NULL
of	NULL
recep-tors	NULL
,	NULL
have	NULL
comparable	NULL
functional	NULL
effects	NULL
on	NULL
B-CLL	NULL
cells	NULL
.	NULL

©	NULL
1997	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

IL-10	NULL
is	NULL
a	NULL
Th2-type	NULL
cytokine	NULL
,	NULL
initially	NULL
identified	NULL
by	NULL
its	NULL
ability	NULL
to	NULL
suppress	NULL
macrophage	NULL
cytokine	NULL
production	NULL
.	NULL
``	NULL

''	NULL
IL-10	NULL
prevents	NULL
programmed	NULL
cell	NULL
death	NULL
of	NULL
both	NULL
normal	NULL
human	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
and	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-in-fected	NULL
B	NULL
cells	NULL
.	NULL
``	NULL

However	NULL
,	NULL
IL-10	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
to	NULL
induce	NULL
apoptosis	NULL
in	NULL
B-CLL	NULL
cells	NULL
.	NULL
``	NULL

Data	NULL
on	NULL
the	NULL
production	NULL
of	NULL
IL-10	NULL
during	NULL
progression	NULL
of	NULL
B-CLL	NULL
have	NULL
been	NULL
equivo-cal	NULL
.	NULL
``	NULL

To	NULL
further	NULL
analyze	NULL
this	NULL
apparent	NULL
difference	NULL
in	NULL
the	NULL
function	NULL
of	NULL
IL-10	NULL
on	NULL
B-CLL	NULL
cells	NULL
compared	NULL
with	NULL
other	NULL
B	NULL
cells	NULL
,	NULL
we	NULL
undertook	NULL
an	NULL
extensive	NULL
characterization	NULL
of	NULL
IL-10	NULL
receptor	NULL
expression	NULL
on	NULL
freshly	NULL
isolated	NULL
B-CLL	NULL
cells	NULL
and	NULL
studied	NULL
the	NULL
functional	NULL
consequences	NULL
of	NULL
IL-10	NULL
binding	NULL
to	NULL
its	NULL
receptor	NULL
on	NULL
this	NULL
malignant	NULL
B-cell	NULL
population	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Patients	NULL
.	NULL

-	NULL
Fresh	NULL
blood	NULL
samples	NULL
were	NULL
obtained	NULL
from	NULL
patients	NULL
previously	NULL
diagnosed	NULL
with	NULL
CD19/CDS5	NULL
positive	NULL
B-CLL	NULL
,	NULL
``	NULL
who	NULL
had	NULL
been	NULL
off	NULL
all	NULL
treatment	NULL
,	NULL
including	NULL
corticosteroids	NULL
,	NULL
for	NULL
at	NULL
least	NULL
30	NULL
days	NULL
.	NULL

The	NULL
percent	NULL
of	NULL
CD19/CD5	NULL
positive	NULL
cells	NULL
in	NULL
the	NULL
mononuclear	NULL
fraction	NULL
was	NULL
always	NULL
>	NULL
=85	NULL
%	NULL
.	NULL

All	NULL
patients	NULL
signed	NULL
informed	NULL
consent	NULL
to	NULL
participate	NULL
in	NULL
this	NULL
study	NULL
that	NULL
was	NULL
approved	NULL
by	NULL
the	NULL
Institutional	NULL
Review	NULL
Board	NULL
of	NULL
Roswell	NULL
Park	NULL
Cancer	NULL
Institute	NULL
.	NULL

Binding	NULL
of	NULL
radiolabeled	NULL
IL-10	NULL
to	NULL
B-CLL	NULL
cells	NULL
.	NULL

-	NULL
Mononuclear	NULL
cells	NULL
(	NULL
MNCs	NULL
)	NULL
were	NULL
isolated	NULL
from	NULL
fresh	NULL
blood	NULL
by	NULL
Ficoll	NULL
separation	NULL
(	NULL
Histo-paque	NULL
;	NULL
Sigma	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
and	NULL
shipped	NULL
overnight	NULL
on	NULL
wet	NULL
ice	NULL
to	NULL
Schering-Plough	NULL
Research	NULL
Institute	NULL
(	NULL
Kenil-worth	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Patient	NULL
samples	NULL
used	NULL
for	NULL
binding	NULL
studies	NULL
had	NULL
a	NULL
median	NULL
CD19/CD3	NULL
expression	NULL
of	NULL
97	NULL
%	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
.	NULL

The	NULL
viability	NULL
following	NULL
overnight	NULL
shipment	NULL
was	NULL
greater	NULL
than	NULL
85	NULL
%	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

The	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
tested	NULL
for	NULL
specific	NULL
binding	NULL
using	NULL
'**-labeled	NULL
recombinant	NULL
human	NULL
IL-10	NULL
(	NULL
'	NULL
``	NULL
I-IL-10	NULL
;	NULL
DuPont-NEN	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

In	NULL
saturation	NULL
binding	NULL
experiments	NULL
,	NULL
twofold	NULL
serial	NULL
dilutions	NULL
(	NULL
from	NULL
0.1	NULL
to	NULL
2.5	NULL
nmol/	NULL
L	NULL
)	NULL
of	NULL
'	NULL
``	NULL
[	NULL
-IL-10	NULL
were	NULL
used	NULL
.	NULL

Nonspecific	NULL
binding	NULL
was	NULL
determined	NULL
in	NULL
a	NULL
parallel	NULL
series	NULL
of	NULL
experiments	NULL
using	NULL
identical	NULL
dilutions	NULL
of	NULL
``	NULL
``	NULL
I-IL-10	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,000-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
IL-10	NULL
(	NULL
Schering-Plough	NULL
Research	NULL
Institute	NULL
)	NULL
.	NULL

The	NULL
dissociation	NULL
constant	NULL
(	NULL
kd	NULL
)	NULL
and	NULL
maximal	NULL
concentration	NULL
of	NULL
ligand	NULL
bound	NULL
to	NULL
cells	NULL
(	NULL
B	NULL
,	NULL
,	NULL
,	NULL
)	NULL
was	NULL
calculated	NULL
by	NULL
Scatchard	NULL
analysis	NULL
,	NULL
using	NULL
linear	NULL
regression	NULL
analysis	NULL
with	NULL
the	NULL
EBDA	NULL
program	NULL
(	NULL
Elsevier-Biosoft	NULL
,	NULL
Cambridge	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

The	NULL
results	NULL
of	NULL
Blood	NULL
,	NULL
Vol	NULL
89	NULL
,	NULL
No	NULL
11	NULL
(	NULL
June	NULL
1	NULL
)	NULL
,	NULL
1997	NULL
:	NULL
pp	NULL
4146-4152	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IL-10	NULL
RECEPTOR	NULL
EXPRESSION	NULL
IN	NULL
CLL	NULL
Table	NULL
1	NULL
.	NULL

Binding	NULL
of	NULL
Radiolabeled	NULL
IL-10	NULL
to	NULL
Fresh	NULL
B-CLL	NULL
Cells	NULL
Experiment	NULL
CPM	NULL
CPM*	NULL
1	NULL
2,370	NULL
424	NULL
2	NULL
3,100	NULL
459	NULL
3	NULL
3,539	NULL
1,273	NULL
4	NULL
3,040	NULL
2,034	NULL
5	NULL
3,301	NULL
1,196	NULL
6	NULL
4,691	NULL
2,070	NULL
7	NULL
2,126	NULL
711	NULL
8	NULL
3,215	NULL
695	NULL
9	NULL
2,518	NULL
992	NULL
Mean	NULL
+	NULL
SEM	NULL
3,100	NULL
+	NULL
252	NULL
1,023	NULL
+	NULL
205	NULL
P	NULL
valuet	NULL
<	NULL
.0005	NULL
Binding	NULL
of	NULL
'*	NULL
``	NULL
l-recombinant	NULL
human	NULL
IL-10	NULL
to	NULL
5	NULL
x	NULL
10°	NULL
freshly	NULL
isolated	NULL
MNCs	NULL
from	NULL
9	NULL
patients	NULL
with	NULL
B-CLL	NULL
(	NULL
mean	NULL
of	NULL
assays	NULL
performed	NULL
in	NULL
tripli-cate	NULL
)	NULL
.	NULL

*	NULL
With	NULL
1,000-fold	NULL
molar	NULL
excess	NULL
unlabeled	NULL
IL-10	NULL
.	NULL

t	NULL
Student	NULL
's	NULL
paired	NULL
test	NULL
.	NULL

Scatchard	NULL
analysis	NULL
were	NULL
replotted	NULL
using	NULL
the	NULL
Cricket	NULL
Graph	NULL
program	NULL
(	NULL
Computer	NULL
Associates	NULL
International	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
and	NULL
supershift	NULL
assay	NULL
.	NULL

Frozen	NULL
patient	NULL
MNC	NULL
samples	NULL
were	NULL
thawed	NULL
,	NULL
ficolled	NULL
,	NULL
and	NULL
washed	NULL
to	NULL
eliminate	NULL
nonviable	NULL
cells	NULL
.	NULL

Following	NULL
overnight	NULL
adherence	NULL
,	NULL
the	NULL
viability	NULL
was	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
in	NULL
all	NULL
experiments	NULL
,	NULL
except	NULL
one	NULL
where	NULL
it	NULL
was	NULL
75	NULL
%	NULL
.	NULL

Between	NULL
91	NULL
%	NULL
and	NULL
99	NULL
%	NULL
of	NULL
cells	NULL
had	NULL
coexpression	NULL
of	NULL
CD19	NULL
and	NULL
CD5	NULL
on	NULL
flow	NULL
cytometric	NULL
analysis	NULL
.	NULL

Ten	NULL
million	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
IL-10	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
for	NULL
15	NULL
minutes	NULL
.	NULL

EMSA	NULL
with	NULL
whole	NULL
cell	NULL
extracts	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
using	NULL
end-labeled	NULL
oligonucleotide	NULL
substrates	NULL
containing	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
sis-inducible	NULL
element	NULL
(	NULL
SIE	NULL
)	NULL
(	NULL
upper	NULL
strand	NULL
,	NULL
GATCCATTTCCCGTA-AATCA	NULL
)	NULL
.	NULL
``	NULL

In	NULL
one	NULL
experiment	NULL
,	NULL
the	NULL
EMSA	NULL
was	NULL
performed	NULL
in	NULL
parallel	NULL
on	NULL
freshly	NULL
isolated	NULL
and	NULL
frozen	NULL
cells	NULL
from	NULL
the	NULL
same	NULL
patient	NULL
with	NULL
identical	NULL
results	NULL
.	NULL

For	NULL
the	NULL
supershift	NULL
studies	NULL
,	NULL
specific	NULL
antibodies	NULL
reactive	NULL
against	NULL
STAT1	NULL
(	NULL
Transduction	NULL
Laboratories	NULL
,	NULL
Lexington	NULL
,	NULL
KY	NULL
)	NULL
or	NULL
STAT3	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
Inc	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
were	NULL
included	NULL
in	NULL
the	NULL
reaction	NULL
mixture	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Determination	NULL
of	NULL
proliferation	NULL
and	NULL
differentiation	NULL
.	NULL

The	NULL
median	NULL
coexpression	NULL
of	NULL
CD5	NULL
and	NULL
CD19	NULL
on	NULL
MNCs	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
was	NULL
96.5	NULL
%	NULL
.	NULL

For	NULL
proliferation	NULL
assays	NULL
,	NULL
cells	NULL
were	NULL
plated	NULL
in	NULL
triplicate	NULL
in	NULL
96-well	NULL
U-bottom	NULL
plates	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
2	NULL
X	NULL
10°	NULL
cells/mL	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
200	NULL
L	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
antibiotics	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
IL-10	NULL
at	NULL
concentrations	NULL
between	NULL
5	NULL
to	NULL
100	NULL
ng/mL	NULL
,	NULL
and	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
100	NULL
ng/mL	NULL
12-O-tetradecanoyl	NULL
13-acetate	NULL
(	NULL
TPA	NULL
)	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

IL-10	NULL
and	NULL
TPA	NULL
were	NULL
added	NULL
together	NULL
at	NULL
the	NULL
indicated	NULL
amounts	NULL
only	NULL
at	NULL
the	NULL
initiation	NULL
of	NULL
cultures	NULL
.	NULL

Wells	NULL
were	NULL
pulsed	NULL
with	NULL
1	NULL
Ci	NULL
methyl-	NULL
[	NULL
``	NULL
H	NULL
]	NULL
thymidine	NULL
(	NULL
ICN	NULL
,	NULL
Costa	NULL
Mesa	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
the	NULL
last	NULL
16	NULL
hours	NULL
of	NULL
the	NULL
7-day	NULL
culture	NULL
,	NULL
incorporated	NULL
thymidine	NULL
was	NULL
measured	NULL
on	NULL
a	NULL
scintillation	NULL
counter	NULL
.	NULL

For	NULL
differentiation	NULL
assays	NULL
,	NULL
fresh	NULL
MNCs	NULL
were	NULL
plated	NULL
in	NULL
24-well	NULL
tissue	NULL
culture	NULL
plates	NULL
(	NULL
Sarstedt	NULL
,	NULL
Newton	NULL
,	NULL
NC	NULL
)	NULL
at	NULL
2	NULL
x	NULL
10¢/mL	NULL
in	NULL
2	NULL
mL	NULL
RPMI	NULL
1640	NULL
plus	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
antibiotics	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
25	NULL
ng/mL	NULL
IL-10	NULL
,	NULL
with	NULL
or	NULL
without	NULL
100	NULL
ng/mL	NULL
of	NULL
TPA	NULL
.	NULL

Following	NULL
culture	NULL
for	NULL
7	NULL
days	NULL
,	NULL
IgM	NULL
concentrations	NULL
were	NULL
determined	NULL
in	NULL
duplicate	NULL
by	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Culture	NULL
conditions	NULL
for	NULL
study	NULL
of	NULL
survival	NULL
.	NULL

MNCs	NULL
were	NULL
isolated	NULL
from	NULL
fresh	NULL
blood	NULL
by	NULL
Ficoll	NULL
separation	NULL
(	NULL
Histopaque	NULL
)	NULL
,	NULL
washed	NULL
,	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
and	NULL
brought	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
=2	NULL
x	NULL
10°	NULL
cells/mL	NULL
.	NULL

Each	NULL
well	NULL
contained	NULL
2	NULL
mL	NULL
.	NULL

At	NULL
initiation	NULL
,	NULL
cultures	NULL
were	NULL
supplemented	NULL
with	NULL
25	NULL
ng/mL	NULL
IL-10	NULL
,	NULL
5	NULL
x	NULL
10~*	NULL
mol/L	NULL
hydrocortisone	NULL
(	NULL
HC	NULL
)	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
IFN-y	NULL
(	NULL
100	NULL
U/	NULL
mL	NULL
;	NULL
Peprotech	NULL
,	NULL
Rocky	NULL
Hill	NULL
,	NULL
NJ	NULL
)	NULL
,	NULL
combinations	NULL
of	NULL
HC	NULL
+	NULL
IL-10	NULL
,	NULL
HC	NULL
4147	NULL
+	NULL
IFN-y	NULL
or	NULL
neither	NULL
,	NULL
and	NULL
then	NULL
cultured	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
wells	NULL
were	NULL
harvested	NULL
at	NULL
24	NULL
hours	NULL
or	NULL
3	NULL
days	NULL
and	NULL
assayed	NULL
for	NULL
viability	NULL
by	NULL
analyzing	NULL
5	NULL
x	NULL
10°	NULL
ungated	NULL
events	NULL
for	NULL
exclusion	NULL
of	NULL
propidium	NULL
iodide	NULL
(	NULL
PI	NULL
)	NULL
on	NULL
a	NULL
FacSort	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Two	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
replicates	NULL
of	NULL
eight	NULL
wells	NULL
to	NULL
determine	NULL
the	NULL
interwell	NULL
variation	NULL
for	NULL
each	NULL
culture	NULL
condition	NULL
(	NULL
estimated	NULL
standard	NULL
deviation	NULL
ranged	NULL
from	NULL
0.58	NULL
%	NULL
to	NULL
2.92	NULL
%	NULL
)	NULL
.	NULL

Thereafter	NULL
,	NULL
a	NULL
single	NULL
well	NULL
J	NULL
>	NULL
wz	NULL
&	NULL
67	NULL
TOTAL	NULL
nd	NULL
5	NULL
=	NULL
sPECIFIC	NULL
§	NULL
+	NULL
2	NULL
s	NULL
E=	NULL
2	NULL
2	NULL
&	NULL
4	NULL
.	NULL

BACKGROUND	NULL
3	NULL
32	NULL
-	NULL
O	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
1	NULL
Q	NULL
0	NULL
0.50	NULL
1	NULL
1.50	NULL
20	NULL
2.503	NULL
'	NULL
»	NULL
5l-rhull-10	NULL
CONCENTRATION	NULL
(	NULL
nM	NULL
)	NULL
0.01	NULL
~	NULL
0.005	NULL
BOUND/FREE	NULL
RATIO	NULL
Bounp	NULL
'*	NULL
``	NULL
I-rhutlL-10	NULL
(	NULL
PM	NULL
)	NULL
Fig	NULL
1	NULL
.	NULL

-	NULL
IL-10	NULL
receptor	NULL
expression	NULL
on	NULL
B-CLL	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
MNCs	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
)	NULL
from	NULL
a	NULL
B-CLL	NULL
patient	NULL
,	NULL
containing	NULL
97	NULL
%	NULL
CD19/CD5	NULL
positive	NULL
B-CLL	NULL
cells	NULL
,	NULL
were	NULL
incubated	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
radiolabeled	NULL
IL-10	NULL
with	NULL
or	NULL
without	NULL
a	NULL
1,000-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
IL-10	NULL
.	NULL

Points	NULL
shown	NULL
are	NULL
averages	NULL
of	NULL
duplicates	NULL
,	NULL
with	NULL
a	NULL
standard	NULL
deviation	NULL
of	NULL
less	NULL
than	NULL
15	NULL
%	NULL
.	NULL

The	NULL
specific	NULL
binding	NULL
was	NULL
determined	NULL
as	NULL
the	NULL
difference	NULL
between	NULL
the	NULL
total	NULL
CPM	NULL
and	NULL
the	NULL
CPM	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,000-fold	NULL
excess	NULL
unlabeled	NULL
IL-10	NULL
.	NULL

Maximal	NULL
binding	NULL
occurs	NULL
at	NULL
1.5	NULL
to	NULL
2.5	NULL
nmol/L	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Scatchard	NULL
analysis	NULL
of	NULL
equilibrium	NULL
binding	NULL
data	NULL
from	NULL
the	NULL
same	NULL
patient	NULL
sample	NULL
as	NULL
shown	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

The	NULL
kd	NULL
derived	NULL
is	NULL
306	NULL
pmol/L	NULL
and	NULL
the	NULL
Bmax	NULL
is	NULL
4.8	NULL
pmol/L	NULL
,	NULL
giving	NULL
an	NULL
estimate	NULL
of	NULL
116	NULL
IL-10	NULL
receptors	NULL
per	NULL
cell	NULL
.	NULL

These	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
such	NULL
experiments	NULL
from	NULL
three	NULL
different	NULL
B-CLL	NULL
patients	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

4148	NULL
JURLANDER	NULL
ET	NULL
AL	NULL
o	NULL
100	NULL
ng/ml	NULL
rhu	NULL
IL-10	NULL
,	NULL
15	NULL
min	NULL
.	NULL

-	NULL
!	NULL

_	NULL
,	NULL
__UPN	NULL
1	NULL
__	NULL
UPN	NULL
2	NULL
_	NULL
UPN	NULL
3	NULL
__	NULL
UPN	NULL
4	NULL
_	NULL
UPN	NULL
5	NULL
_	NULL
UPN	NULL
6	NULL
4	NULL
2	NULL
s	NULL
4	NULL
a	NULL
s	NULL
1	NULL
a	NULL
s	NULL
1	NULL
a	NULL
s	NULL
9	NULL
za	NULL
s	NULL
1	NULL
za	NULL
s	NULL
)	NULL
'	NULL
'	NULL
'	NULL
WR	NULL
__	NULL
<	NULL
-stats	NULL
&	NULL
f	NULL
$	NULL
Supershifted	NULL
complexes	NULL
<	NULL
4-STAT1	NULL
<	NULL
4-SIF	NULL
-	NULL
A	NULL
Fig	NULL
2	NULL
.	NULL

-	NULL
IL-10	NULL
receptor	NULL
signal	NULL
transduction	NULL
in	NULL
B-CLL	NULL
cells	NULL
.	NULL

MNCs	NULL
(	NULL
1	NULL
x	NULL
10	NULL
``	NULL
)	NULL
containing	NULL
a	NULL
median	NULL
of	NULL
93	NULL
%	NULL
CD19/CD5	NULL
positive	NULL
B-CLL	NULL
cells	NULL
from	NULL
6	NULL
patients	NULL
with	NULL
B-CLL	NULL
were	NULL
stimulated	NULL
with	NULL
IL-10	NULL
(	NULL
100	NULL
ng/mL	NULL
)	NULL
for	NULL
15	NULL
minutes	NULL
.	NULL

Whole	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
subjected	NULL
to	NULL
EMSA	NULL
using	NULL
SIE	NULL
as	NULL
a	NULL
probe	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
lane	NULL
to	NULL
the	NULL
far	NULL
left	NULL
identifies	NULL
an	NULL
EMSA	NULL
with	NULL
B-CLL	NULL
cells	NULL
(	NULL
UPN	NULL
2	NULL
)	NULL
and	NULL
the	NULL
SIE	NULL
probe	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-10	NULL
(	NULL
negative	NULL
control	NULL
)	NULL
.	NULL

For	NULL
each	NULL
UPN	NULL
,	NULL
lane	NULL
1	NULL
identifies	NULL
an	NULL
EMSA	NULL
with	NULL
B-CLL	NULL
cells	NULL
and	NULL
the	NULL
SIE	NULL
probe	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-10	NULL
,	NULL
giving	NULL
rise	NULL
to	NULL
SIF-A	NULL
,	NULL
-B	NULL
,	NULL
and	NULL
-C	NULL
complex	NULL
as	NULL
indicated	NULL
on	NULL
the	NULL
right	NULL
.	NULL

For	NULL
each	NULL
UPN	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
identify	NULL
an	NULL
electrophoretic	NULL
mobility	NULL
supershift	NULL
assay	NULL
with	NULL
B-CLL	NULL
cells	NULL
,	NULL
the	NULL
SIE	NULL
probe	NULL
,	NULL
IL-10	NULL
,	NULL
and	NULL
an	NULL
antibody	NULL
specific	NULL
for	NULL
STAT3	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
STATA	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
arrows	NULL
identify	NULL
STAT1	NULL
and	NULL
STAT3	NULL
MoAb-mediated	NULL
supershift	NULL
in	NULL
all	NULL
six	NULL
patient	NULL
samples	NULL
.	NULL

was	NULL
analyzed	NULL
for	NULL
each	NULL
culture	NULL
condition	NULL
in	NULL
an	NULL
additional	NULL
five	NULL
consecutive	NULL
cases	NULL
of	NULL
B-CLL	NULL
.	NULL

Median	NULL
coexpression	NULL
of	NULL
CD19	NULL
and	NULL
CDS	NULL
on	NULL
MNCs	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
was	NULL
91	NULL
%	NULL
.	NULL

Measurement	NULL
of	NULL
apoptosis	NULL
and	NULL
bel-2	NULL
protein	NULL
expression	NULL
.	NULL

For	NULL
quantitation	NULL
of	NULL
programmed	NULL
cell	NULL
death	NULL
,	NULL
B-CLL	NULL
nuclei	NULL
were	NULL
stained	NULL
with	NULL
PI	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
as	NULL
described	NULL
.	NULL
``	NULL

For	NULL
analysis	NULL
of	NULL
bel-2	NULL
protein	NULL
expression	NULL
,	NULL
1	NULL
%	NULL
10°	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
phycoer-ythrin	NULL
(	NULL
PE	NULL
)	NULL
-conjugated	NULL
anti-CD19	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
or	NULL
a	NULL
directly-conjugated	NULL
nonreactive	NULL
isotype	NULL
control	NULL
monoclonal	NULL
antibody	NULL
(	NULL
MoAb	NULL
)	NULL
and	NULL
then	NULL
permeabilized	NULL
for	NULL
30	NULL
minutes	NULL
on	NULL
ice	NULL
in	NULL
Ortho	NULL
Permea	NULL
Fix	NULL
(	NULL
Ortho	NULL
Diagnostic	NULL
Systems	NULL
,	NULL
Raritan	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Permeabilization	NULL
,	NULL
as	NULL
examined	NULL
by	NULL
vital	NULL
dye	NULL
,	NULL
was	NULL
100	NULL
%	NULL
in	NULL
cells	NULL
under	NULL
all	NULL
culture	NULL
conditions	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
bel-2	NULL
antibody	NULL
(	NULL
DAKO	NULL
,	NULL
Glostrup	NULL
,	NULL
Denmark	NULL
)	NULL
,	NULL
or	NULL
a	NULL
directly-conjugated	NULL
nonreactive	NULL
isotype	NULL
control	NULL
MoAb	NULL
,	NULL
washed	NULL
twice	NULL
and	NULL
analyzed	NULL
for	NULL
simultaneous	NULL
fluorescence	NULL
of	NULL
FITC	NULL
and	NULL
PE	NULL
.	NULL

Ten	NULL
thousand	NULL
events	NULL
were	NULL
collected	NULL
and	NULL
the	NULL
median	NULL
fluorescence	NULL
intensity	NULL
(	NULL
MFI	NULL
)	NULL
was	NULL
measured	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Background	NULL
fluorescence	NULL
with	NULL
nonreactive	NULL
control	NULL
MoAbs	NULL
was	NULL
always	NULL
within	NULL
the	NULL
first	NULL
log	NULL
of	NULL
fluorescence	NULL
intensity	NULL
.	NULL

Statistical	NULL
analysis	NULL
.	NULL

-	NULL
Both	NULL
the	NULL
matched-pairs	NULL
t-test	NULL
and	NULL
the	NULL
Wil-coxon	NULL
signed	NULL
rank	NULL
sum	NULL
test	NULL
were	NULL
used	NULL
to	NULL
compare	NULL
assay	NULL
results	NULL
from	NULL
patient	NULL
samples	NULL
with	NULL
different	NULL
conditions	NULL
.	NULL

The	NULL
standard	NULL
deviation	NULL
of	NULL
the	NULL
within-patient	NULL
variation	NULL
of	NULL
the	NULL
percent	NULL
viability	NULL
determined	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
exclusion	NULL
of	NULL
PI	NULL
for	NULL
various	NULL
conditions	NULL
was	NULL
estimated	NULL
from	NULL
the	NULL
counts	NULL
obtained	NULL
using	NULL
replicates	NULL
of	NULL
eight	NULL
wells	NULL
for	NULL
each	NULL
of	NULL
two	NULL
patients	NULL
.	NULL

The	NULL
average	NULL
of	NULL
these	NULL
two	NULL
estimated	NULL
values	NULL
was	NULL
used	NULL
as	NULL
the	NULL
estimated	NULL
standard	NULL
deviation	NULL
for	NULL
the	NULL
corresponding	NULL
condition	NULL
.	NULL

The	NULL
standard	NULL
deviation	NULL
of	NULL
the	NULL
difference	NULL
in	NULL
percent	NULL
viability	NULL
based	NULL
on	NULL
counts	NULL
from	NULL
a	NULL
single	NULL
well	NULL
was	NULL
conservatively	NULL
estimated	NULL
as	NULL
the	NULL
square	NULL
root	NULL
of	NULL
the	NULL
sum	NULL
of	NULL
the	NULL
squares	NULL
of	NULL
the	NULL
estimated	NULL
standard	NULL
deviations	NULL
for	NULL
the	NULL
two	NULL
conditions	NULL
being	NULL
compared	NULL
.	NULL

RESULTS	NULL
IL-10	NULL
receptor	NULL
expression	NULL
on	NULL
human	NULL
B-CLL	NULL
cells	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
IL-10	NULL
could	NULL
bind	NULL
specifically	NULL
to	NULL
B-CLL	NULL
cells	NULL
,	NULL
fresh	NULL
MNCs	NULL
from	NULL
nine	NULL
patients	NULL
were	NULL
assayed	NULL
for	NULL
'	NULL
``	NULL
I-IL-10	NULL
binding	NULL
.	NULL

Results	NULL
of	NULL
this	NULL
assay	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
and	NULL
indicate	NULL
that	NULL
B-CLL	NULL
cells	NULL
bind	NULL
IL-10	NULL
with	NULL
a	NULL
significant	NULL
degree	NULL
of	NULL
specificity	NULL
(	NULL
P	NULL
<	NULL
.0005	NULL
)	NULL
.	NULL

To	NULL
further	NULL
assess	NULL
for	NULL
IL-10	NULL
receptor	NULL
protein	NULL
expression	NULL
on	NULL
B-CLL	NULL
cells	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
binding	NULL
affinity	NULL
and	NULL
estimated	NULL
the	NULL
number	NULL
of	NULL
binding	NULL
sites	NULL
per	NULL
cell	NULL
.	NULL

Saturation	NULL
binding	NULL
was	NULL
performed	NULL
on	NULL
freshly	NULL
isolated	NULL
B-CLL	NULL
cells	NULL
from	NULL
three	NULL
patients	NULL
.	NULL

Figure	NULL
1A	NULL
and	NULL
Fig	NULL
1B	NULL
show	NULL
the	NULL
binding	NULL
curve	NULL
and	NULL
the	NULL
derived	NULL
Scatchard	NULL
plot	NULL
,	NULL
respectively	NULL
,	NULL
from	NULL
one	NULL
patient	NULL
.	NULL

The	NULL
derived	NULL
kd	NULL
is	NULL
306	NULL
pmol/	NULL
L	NULL
and	NULL
the	NULL
B	NULL
,	NULL
,	NULL
,	NULL
,	NULL
is	NULL
4.8	NULL
pmol/L	NULL
.	NULL

The	NULL
other	NULL
two	NULL
patient	NULL
samples	NULL
showed	NULL
kd	NULL
values	NULL
of	NULL
168	NULL
and	NULL
426	NULL
pm	NULL
and	NULL
B	NULL
;	NULL
,	NULL
,	NULL
,	NULL
,	NULL
values	NULL
of	NULL
1.9	NULL
and	NULL
5.3	NULL
pmol/L	NULL
,	NULL
respectively	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
results	NULL
indicate	NULL
that	NULL
IL-10	NULL
binds	NULL
its	NULL
receptor	NULL
on	NULL
B-CLL	NULL
cells	NULL
with	NULL
an	NULL
affinity	NULL
in	NULL
the	NULL
range	NULL
of	NULL
1.9	NULL
to	NULL
5.3	NULL
pmol/L	NULL
.	NULL

Maximal	NULL
binding	NULL
of	NULL
IL-10	NULL
occurs	NULL
at	NULL
approximately	NULL
1.5	NULL
to	NULL
2.5	NULL
nmol/L	NULL
.	NULL

If	NULL
one	NULL
assumes	NULL
that	NULL
each	NULL
IL-10	NULL
receptor	NULL
unit	NULL
binds	NULL
one	NULL
dimer	NULL
of	NULL
human	NULL
IL-10	NULL
ligand	NULL
,	NULL
``	NULL
then	NULL
these	NULL
data	NULL
provide	NULL
an	NULL
estimate	NULL
of	NULL
approximately	NULL
47	NULL
to	NULL
120	NULL
IL-10	NULL
receptors	NULL
per	NULL
cell	NULL
for	NULL
B-CLL	NULL
cells	NULL
.	NULL

IL-10	NULL
receptor	NULL
signal	NULL
transduction	NULL
in	NULL
B-CLL	NULL
cells	NULL
.	NULL

We	NULL
next	NULL
assessed	NULL
whether	NULL
the	NULL
IL-10	NULL
receptor	NULL
expressed	NULL
on	NULL
B-CLL	NULL
cells	NULL
was	NULL
capable	NULL
of	NULL
intracellular	NULL
signal	NULL
transduction	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
proteins	NULL
following	NULL
IL-10	NULL
stimulation	NULL
of	NULL
normal	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
involves	NULL
phosphorylation	NULL
of	NULL
STAT1	NULL
and	NULL
STAT3	NULL
in	NULL
both	NULL
instances	NULL
.	NULL
``	NULL

Nonadbherent	NULL
MNCs	NULL
containing	NULL
a	NULL
median	NULL
of	NULL
93	NULL
%	NULL
B-CLL	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
six	NULL
B-CLL	NULL
patients	NULL
and	NULL
stimulated	NULL
with	NULL
IL-10	NULL
for	NULL
15	NULL
minutes	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
were	NULL
observed	NULL
using	NULL
the	NULL
SIE	NULL
probe	NULL
in	NULL
all	NULL
six	NULL
samples	NULL
(	NULL
Fig	NULL
2	NULL
)	NULL
.	NULL

The	NULL
complexes	NULL
were	NULL
resolved	NULL
into	NULL
three	NULL
bands	NULL
generically	NULL
termed	NULL
SIF-A	NULL
,	NULL
-B	NULL
,	NULL
and	NULL
-C.	NULL
``	NULL
To	NULL
define	NULL
the	NULL
identity	NULL
of	NULL
these	NULL
IL-10-induced	NULL
STAT	NULL
proteins	NULL
,	NULL
the	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IL-10	NULL
RECEPTOR	NULL
EXPRESSION	NULL
IN	NULL
CLL	NULL
whole	NULL
cell	NULL
lysates	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-STAT1	NULL
and	NULL
anti-STAT3	NULL
antibodies	NULL
in	NULL
a	NULL
supershift	NULL
EMSA	NULL
.	NULL

A	NULL
supershift	NULL
identified	NULL
SIF-A	NULL
,	NULL
-B	NULL
,	NULL
-C	NULL
as	NULL
STAT3	NULL
homodimer	NULL
,	NULL
STATI-STAT3	NULL
heterodimer	NULL
and	NULL
STAT	NULL
homodimer	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
2	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
STAT	NULL
phosphorylation	NULL
was	NULL
not	NULL
seen	NULL
following	NULL
stimulation	NULL
with	NULL
IL-2	NULL
,	NULL
despite	NULL
functional	NULL
evidence	NULL
of	NULL
IL-2	NULL
receptors	NULL
on	NULL
B-CLL	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL
``	NULL

Proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
B-CLL	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
IL-10	NULL
.	NULL

To	NULL
further	NULL
assess	NULL
functional	NULL
responsiveness	NULL
of	NULL
IL-10	NULL
receptor	NULL
expression	NULL
on	NULL
B-CLL	NULL
cells	NULL
,	NULL
we	NULL
evaluated	NULL
both	NULL
proliferation	NULL
and	NULL
differentiation	NULL
.	NULL

MNCs	NULL
from	NULL
five	NULL
patients	NULL
containing	NULL
a	NULL
median	NULL
of	NULL
96.5	NULL
%	NULL
B-CLL	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
7	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
5	NULL
to	NULL
100	NULL
ng/mL	NULL
.	NULL

of	NULL
IL-10	NULL
,	NULL
with	NULL
or	NULL
without	NULL
TPA	NULL
.	NULL

A	NULL
7-day	NULL
culture	NULL
was	NULL
performed	NULL
to	NULL
compare	NULL
our	NULL
results	NULL
with	NULL
those	NULL
reported	NULL
for	NULL
CD4O-activated	NULL
B-CLL	NULL
cells	NULL
and	NULL
IL-10	NULL
.	NULL

``	NULL
°	NULL
Proliferation	NULL
was	NULL
assayed	NULL
by	NULL
*H-thymidine	NULL
incorporation	NULL
.	NULL

IL-10	NULL
alone	NULL
did	NULL
not	NULL
induce	NULL
any	NULL
significant	NULL
DNA	NULL
synthesis	NULL
in	NULL
resting	NULL
B-CLL	NULL
cells	NULL
at	NULL
any	NULL
concentration	NULL
.	NULL

However	NULL
,	NULL
IL-10	NULL
consistently	NULL
and	NULL
significantly	NULL
inhibited	NULL
the	NULL
TPA-induced	NULL
proliferation	NULL
at	NULL
IL-10	NULL
concentrations	NULL
above	NULL
10	NULL
ng/mL	NULL
,	NULL
and	NULL
did	NULL
so	NULL
in	NULL
a	NULL
dose-depen-dent	NULL
fashion	NULL
(	NULL
P	NULL
<	NULL
.01	NULL
,	NULL
Fig	NULL
3A	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
this	NULL
,	NULL
25	NULL
ng/mL	NULL
of	NULL
IL-10	NULL
was	NULL
chosen	NULL
as	NULL
the	NULL
standard	NULL
dose	NULL
in	NULL
further	NULL
experi-ments	NULL
.	NULL

MNCs	NULL
from	NULL
10	NULL
patients	NULL
also	NULL
containing	NULL
a	NULL
median	NULL
of	NULL
96.5	NULL
%	NULL
B-CLL	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
7	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
IL-10	NULL
with	NULL
or	NULL
without	NULL
simultaneous	NULL
activation	NULL
by	NULL
TPA	NULL
.	NULL

IL-10	NULL
was	NULL
noted	NULL
to	NULL
significantly	NULL
enhance	NULL
TPA-induced	NULL
IgM	NULL
production	NULL
in	NULL
all	NULL
10	NULL
patients	NULL
samples	NULL
(	NULL
P	NULL
<	NULL
.05	NULL
,	NULL
Fig	NULL
3B	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
IL-10	NULL
on	NULL
B-CLL	NULL
cell	NULL
survival	NULL
.	NULL

-	NULL
Survival	NULL
was	NULL
studied	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
exogenous	NULL
factors	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-10	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
HC	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
,	NULL
``	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IFN-y	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
prolongation	NULL
of	NULL
survival	NULL
,	NULL
``	NULL
or	NULL
in	NULL
combinations	NULL
of	NULL
HC	NULL
with	NULL
either	NULL
IL-10	NULL
or	NULL
IFN-y	NULL
.	NULL

The	NULL
results	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

IFN-y	NULL
always	NULL
improved	NULL
viability	NULL
and	NULL
HC	NULL
always	NULL
decreased	NULL
viability	NULL
,	NULL
compared	NULL
with	NULL
B-CLL	NULL
cells	NULL
cultured	NULL
for	NULL
24	NULL
hours	NULL
in	NULL
medium	NULL
alone	NULL
.	NULL

In	NULL
seven	NULL
consecutive	NULL
cases	NULL
of	NULL
B-CLL	NULL
cultured	NULL
for	NULL
24	NULL
hours	NULL
,	NULL
IL-10	NULL
did	NULL
not	NULL
decrease	NULL
viability	NULL
or	NULL
induce	NULL
apoptosis	NULL
when	NULL
compared	NULL
with	NULL
medium	NULL
alone	NULL
.	NULL

Three	NULL
of	NULL
these	NULL
cases	NULL
were	NULL
continued	NULL
in	NULL
culture	NULL
for	NULL
72	NULL
hours	NULL
with	NULL
similar	NULL
results	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

While	NULL
there	NULL
was	NULL
a	NULL
trend	NULL
toward	NULL
improved	NULL
survival	NULL
of	NULL
B-CLL	NULL
cells	NULL
cultured	NULL
with	NULL
IL-10	NULL
compared	NULL
with	NULL
cells	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
in	NULL
six	NULL
of	NULL
the	NULL
seven	NULL
cases	NULL
studied	NULL
,	NULL
this	NULL
did	NULL
not	NULL
reach	NULL
statistical	NULL
significance	NULL
.	NULL

There	NULL
were	NULL
individual	NULL
cases	NULL
of	NULL
B-CLL	NULL
in	NULL
which	NULL
survival	NULL
was	NULL
clearly	NULL
higher	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-10	NULL
,	NULL
compared	NULL
with	NULL
cells	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
.	NULL

For	NULL
example	NULL
,	NULL
unique	NULL
patient	NULL
numbers	NULL
(	NULL
UPNs	NULL
)	NULL
5	NULL
and	NULL
6	NULL
were	NULL
studied	NULL
in	NULL
eight	NULL
parallel	NULL
cultures	NULL
,	NULL
and	NULL
IL-10	NULL
stimulation	NULL
influenced	NULL
viability	NULL
in	NULL
a	NULL
manner	NULL
that	NULL
was	NULL
significantly	NULL
different	NULL
from	NULL
the	NULL
controls	NULL
,	NULL
qualitatively	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
IFN-y	NULL
,	NULL
and	NULL
in	NULL
distinct	NULL
contrast	NULL
to	NULL
that	NULL
of	NULL
HC	NULL
(	NULL
Fig	NULL
4	NULL
)	NULL
.	NULL

IL-10	NULL
,	NULL
like	NULL
IFN-y	NULL
,	NULL
always	NULL
reduced	NULL
HC-induced	NULL
cell	NULL
death	NULL
when	NULL
added	NULL
at	NULL
the	NULL
onset	NULL
of	NULL
culture	NULL
(	NULL
P	NULL
<	NULL
.02	NULL
,	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
these	NULL
studies	NULL
were	NULL
done	NULL
in	NULL
whole	NULL
blood	NULL
cultures	NULL
from	NULL
an	NULL
additional	NULL
12	NULL
consecutive	NULL
patients	NULL
,	NULL
only	NULL
correcting	NULL
for	NULL
culture	NULL
cell	NULL
density	NULL
with	NULL
patients	NULL
'	NULL
autologous	NULL
serum	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

4149	NULL
A	NULL
5—	NULL
a	NULL
~	NULL
4	NULL
ITPA	NULL
IS	NULL
l	NULL
x57	NULL
|	NULL
E	NULL
&	NULL
1	NULL
G	NULL
2	NULL
-	NULL
l	NULL
T	NULL
[	NULL
Brg	NULL
14	NULL
-	NULL
_d	NULL
NO	NULL
TPA	NULL
I	NULL
I	NULL
t	NULL
I	NULL
I	NULL
1	NULL
0	NULL
5	NULL
10	NULL
25	NULL
50	NULL
100	NULL
IL-10	NULL
DOSE	NULL
(	NULL
ng/ml	NULL
)	NULL
5	NULL
0	NULL
07	NULL
4	NULL
0	NULL
O-E	NULL
3	NULL
3	NULL
0	NULL
OS	NULL
=	NULL
20	NULL
0-5	NULL
I	NULL
1	NULL
0	NULL
0-7	NULL
0—1	NULL
a	NULL
oO	NULL
<	NULL
I	NULL
&	NULL
3	NULL
-	NULL
a	NULL
*	NULL
a	NULL
ir	NULL
i-	NULL
L	NULL
_	NULL
c=	NULL
+	NULL
<	NULL
4	NULL
[	NULL
»	NULL
l—	NULL
Fig	NULL
3	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
IL-10	NULL
on	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
B-CLL	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
°H-thymidine	NULL
incorporation	NULL
measured	NULL
in	NULL
4	NULL
x	NULL
10°	NULL
MNCs	NULL
following	NULL
culture	NULL
for	NULL
7	NULL
days	NULL
with	NULL
either	NULL
medium	NULL
alone	NULL
,	NULL
5	NULL
to	NULL
100	NULL
ng/	NULL
mL	NULL
of	NULL
IL-10	NULL
,	NULL
100	NULL
ng/mL	NULL
TPA	NULL
,	NULL
or	NULL
TPA	NULL
plus	NULL
5	NULL
to	NULL
100	NULL
ng/mL	NULL
of	NULL
IL-10	NULL
.	NULL

Experiments	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
and	NULL
represent	NULL
the	NULL
mean	NULL
+	NULL
SEM	NULL
for	NULL
five	NULL
B-CLL	NULL
patients	NULL
.	NULL

(	NULL
B	NULL
)	NULL
IgM	NULL
concentration	NULL
in	NULL
supernatants	NULL
from	NULL
4	NULL
x	NULL
10°	NULL
MNCs	NULL
cultured	NULL
under	NULL
the	NULL
same	NULL
culture	NULL
conditions	NULL
as	NULL
(	NULL
A	NULL
)	NULL
,	NULL
but	NULL
with	NULL
25	NULL
ng/mL	NULL
of	NULL
IL-10	NULL
.	NULL

Experiments	NULL
in	NULL
(	NULL
B	NULL
)	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
and	NULL
represent	NULL
the	NULL
mean	NULL
+	NULL
SEM	NULL
for	NULL
10	NULL
B-CLL	NULL
patients	NULL
.	NULL

The	NULL
MNCs	NULL
studied	NULL
for	NULL
proliferation	NULL
and	NULL
differentiation	NULL
contained	NULL
a	NULL
median	NULL
of	NULL
96.5	NULL
%	NULL
CD19/CD5	NULL
positive	NULL
B-CLL	NULL
cells	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

4150	NULL
JURLANDER	NULL
ET	NULL
AL	NULL
Table	NULL
2	NULL
.	NULL

Effect	NULL
of	NULL
IL-10	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
Hydrocortisone	NULL
on	NULL
Survival	NULL
and	NULL
Apoptosis	NULL
in	NULL
B-CLL	NULL
Cells	NULL
Experimental	NULL
Culture	NULL
Condition	NULL
Medium	NULL
+	NULL
HC	NULL
+	NULL
Medium	NULL
+	NULL
HC	NULL
+	NULL
UPN	NULL
Medium	NULL
Medium	NULL
+	NULL
IL-10	NULL
Medium	NULL
+	NULL
IFN-y	NULL
Medium	NULL
+	NULL
HC	NULL
IL-10	NULL
IFN-y	NULL
%	NULL
V	NULL
%	NULL
A	NULL
%	NULL
V	NULL
%	NULL
A	NULL
%	NULL
V	NULL
%	NULL
A	NULL
%	NULL
V	NULL
%	NULL
A	NULL
%	NULL
V	NULL
%	NULL
A	NULL
%	NULL
V	NULL
%	NULL
A	NULL
1	NULL
90.2	NULL
32.6	NULL
92.6	NULL
13.7	NULL
96.2	NULL
8.8	NULL
63.7	NULL
67.6	NULL
69.8	NULL
57.5	NULL
76.3	NULL
44.5	NULL
2	NULL
90.6	NULL
8.2	NULL
96.3	NULL
6.6	NULL
96.5	NULL
4.5	NULL
79.7	NULL
27.6	NULL
89.8	NULL
16.8	NULL
88.5	NULL
16.8	NULL
3	NULL
94.6	NULL
14.5	NULL
90.3	NULL
13.0	NULL
95.6	NULL
7.4	NULL
65.3	NULL
45.8	NULL
77.1	NULL
37.4	NULL
78.9	NULL
29.7	NULL
4	NULL
83.7	NULL
27.8	NULL
95.1	NULL
10.2	NULL
96.9	NULL
6.7	NULL
74.0	NULL
37.6	NULL
93.3	NULL
13.2	NULL
91.1	NULL
15.0	NULL
5	NULL
90.7	NULL
18.2	NULL
93.5	NULL
13.5	NULL
97.3	NULL
10.3	NULL
76.5	NULL
37.6	NULL
82.4	NULL
25.1	NULL
83.4	NULL
22.2	NULL
6	NULL
88.0	NULL
17.1	NULL
94.3	NULL
13.8	NULL
94.3	NULL
11.7	NULL
59.8	NULL
67.9	NULL
71.3	NULL
53.9	NULL
76.5	NULL
52.9	NULL
7	NULL
96.9	NULL
6.7	NULL
96.9	NULL
5.7	NULL
97.1	NULL
5.6	NULL
90.1	NULL
19.2	NULL
92.9	NULL
13.8	NULL
90.6	NULL
14.4	NULL
Mean	NULL
90.7	NULL
17.9	NULL
94.1	NULL
10.9	NULL
96.3	NULL
7.9	NULL
72.7	NULL
43.3	NULL
82.4	NULL
31.1	NULL
83.6	NULL
27.9	NULL
Abbreviations	NULL
:	NULL
UPN	NULL
,	NULL
unique	NULL
patient	NULL
number	NULL
;	NULL
IL-10	NULL
,	NULL
interleukin-10	NULL
(	NULL
25	NULL
ng/mL	NULL
)	NULL
;	NULL
IFN-y	NULL
,	NULL
interferon	NULL
gamma	NULL
(	NULL
100	NULL
U/mL	NULL
)	NULL
;	NULL
HC	NULL
,	NULL
hydrocortisone	NULL
(	NULL
5	NULL
x	NULL
10*	NULL
mol/L	NULL
)	NULL
;	NULL
%	NULL
V	NULL
,	NULL
percent	NULL
viability	NULL
as	NULL
determined	NULL
by	NULL
PI	NULL
exclusion	NULL
and	NULL
flow	NULL
cytometry	NULL
;	NULL
%	NULL
A	NULL
,	NULL
percent	NULL
apoptosis	NULL
as	NULL
determined	NULL
by	NULL
PI	NULL
nuclear	NULL
staining	NULL
and	NULL
flow	NULL
cytometry	NULL
.	NULL

The	NULL
influence	NULL
of	NULL
IL-10	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
bel-2	NULL
protein	NULL
.	NULL

B-CLL	NULL
cells	NULL
constitutively	NULL
express	NULL
bel-2	NULL
,	NULL
and	NULL
a	NULL
reduction	NULL
of	NULL
bel-2	NULL
protein	NULL
expression	NULL
coincides	NULL
with	NULL
apoptosis	NULL
of	NULL
B-CLL	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL
``	NULL

MNCs	NULL
from	NULL
six	NULL
patients	NULL
containing	NULL
a	NULL
median	NULL
of	NULL
94.5	NULL
%	NULL
B-CLL	NULL
cells	NULL
were	NULL
cultured	NULL
under	NULL
the	NULL
conditions	NULL
described	NULL
above	NULL
for	NULL
viability	NULL
studies	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
bel-2	NULL
protein	NULL
was	NULL
analyzed	NULL
on	NULL
permeabilized	NULL
CD19*	NULL
cells	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

In	NULL
three	NULL
separate	NULL
experiments	NULL
,	NULL
100	NULL
%	NULL
of	NULL
cells	NULL
inside	NULL
the	NULL
lymphocyte	NULL
gate	NULL
maintained	NULL
vital	NULL
dye	NULL
exclusion	NULL
under	NULL
all	NULL
culture	NULL
conditions	NULL
.	NULL

At	NULL
24	NULL
and	NULL
72	NULL
hours	NULL
,	NULL
there	NULL
was	NULL
no	NULL
significant	NULL
difference	NULL
in	NULL
the	NULL
MFI	NULL
of	NULL
bel-2	NULL
protein	NULL
expression	NULL
,	NULL
regardless	NULL
of	NULL
culture	NULL
conditions	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
In	NULL
the	NULL
current	NULL
study	NULL
,	NULL
we	NULL
assess	NULL
the	NULL
expression	NULL
of	NULL
IL-10	NULL
receptors	NULL
on	NULL
B-CLL	NULL
cells	NULL
and	NULL
the	NULL
functional	NULL
consequences	NULL
of	NULL
IL-10	NULL
binding	NULL
to	NULL
these	NULL
receptors	NULL
.	NULL

We	NULL
provide	NULL
the	NULL
first	NULL
documentation	NULL
of	NULL
specific	NULL
IL-10	NULL
binding	NULL
to	NULL
freshly	NULL
isolated	NULL
B-CLL	NULL
cells	NULL
in	NULL
all	NULL
nine	NULL
patient	NULL
samples	NULL
studied	NULL
.	NULL

Saturation	NULL
binding	NULL
experiments	NULL
performed	NULL
with	NULL
'°I-IL-10	NULL
showed	NULL
a	NULL
range	NULL
of	NULL
47	NULL
to	NULL
120	NULL
IL-10	NULL
receptor	NULL
binding	NULL
sites	NULL
per	NULL
cell	NULL
,	NULL
with	NULL
a	NULL
kd	NULL
in	NULL
the	NULL
range	NULL
of	NULL
168	NULL
pmol/L	NULL
to	NULL
426	NULL
pmol/L	NULL
,	NULL
comparable	NULL
to	NULL
other	NULL
IL-10-responsive	NULL
cell	NULL
types	NULL
.	NULL
``	NULL

Between	NULL
91	NULL
%	NULL
and	NULL
99	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
used	NULL
in	NULL
these	NULL
binding	NULL
experiments	NULL
were	NULL
B-CLL	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
our	NULL
estimate	NULL
of	NULL
receptor	NULL
number	NULL
and	NULL
affinity	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
representative	NULL
of	NULL
the	NULL
malignant	NULL
cell	NULL
population	NULL
.	NULL

The	NULL
functional	NULL
responsiveness	NULL
of	NULL
the	NULL
IL-10	NULL
receptor	NULL
to	NULL
its	NULL
ligand	NULL
on	NULL
B-CLL	NULL
cells	NULL
was	NULL
first	NULL
assessed	NULL
by	NULL
the	NULL
phosphorylation	NULL
of	NULL
STAT	NULL
proteins	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
STAT1	NULL
and	NULL
STAT3	NULL
homodimers	NULL
in	NULL
all	NULL
six	NULL
patient	NULL
samples	NULL
studied	NULL
,	NULL
as	NULL
well	NULL
as	NULL
one	NULL
example	NULL
of	NULL
a	NULL
STATI/STAT3	NULL
heterodimer	NULL
following	NULL
IL-10	NULL
stimulation	NULL
,	NULL
was	NULL
identical	NULL
to	NULL
that	NULL
recently	NULL
reported	NULL
for	NULL
UPN	NULL
5	NULL
upN	NULL
6	NULL
100	NULL
100	NULL
13:1	NULL
>	NULL
=s	NULL
9	NULL
0-3	NULL
90	NULL
,	NULL
C	NULL
<	NULL
4	NULL
8	NULL
0-~	NULL
+	NULL
2	NULL
:	NULL
|	NULL
+	NULL
w	NULL
8	NULL
0-C.	NULL
7	NULL
0	NULL
5	NULL
0	NULL
Fig	NULL
4	NULL
.	NULL

-	NULL
Box	NULL
and	NULL
whiskers	NULL
diagram	NULL
of	NULL
survival	NULL
of	NULL
2	NULL
x	NULL
10°/mLl	NULL
B-CLL	NULL
cells	NULL
from	NULL
two	NULL
patients	NULL
(	NULL
UPN	NULL
5	NULL
and	NULL
6	NULL
in	NULL
Table	NULL
2	NULL
)	NULL
cultured	NULL
in	NULL
eight	NULL
parallel	NULL
cultures	NULL
per	NULL
condition	NULL
for	NULL
24	NULL
hours	NULL
in	NULL
medium	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
under	NULL
the	NULL
listed	NULL
conditions	NULL
.	NULL

Viability	NULL
was	NULL
assessed	NULL
by	NULL
Pl-exclusion	NULL
with	NULL
acquisition	NULL
of	NULL
5	NULL
x	NULL
10°	NULL
ungated	NULL
conTRoL	NULL
IL-10	NULL
IFN-y	NULL
HC	NULL
-HC+IL-10-	NULL
CONTROL	NULL
IL-1	NULL
0	NULL
IFN-y	NULL
7	NULL
HC	NULL
events	NULL
on	NULL
a	NULL
flow	NULL
cytometer	NULL
.	NULL

From	NULL
these	NULL
data	NULL
the	NULL
mean	NULL
percent	NULL
viability	NULL
(	NULL
crosses	NULL
)	NULL
,	NULL
the	NULL
95	NULL
%	NULL
confidence	NULL
interval	NULL
for	NULL
estimation	NULL
of	NULL
the	NULL
mean	NULL
(	NULL
boxes	NULL
)	NULL
,	NULL
and	NULL
one	NULL
standard	NULL
deviation	NULL
above	NULL
and	NULL
below	NULL
the	NULL
mean	NULL
(	NULL
bars	NULL
)	NULL
were	NULL
calculated	NULL
.	NULL

HC+IFN-y	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IL-10	NULL
RECEPTOR	NULL
EXPRESSION	NULL
IN	NULL
CLL	NULL
normal	NULL
human	NULL
T-cell	NULL
and	NULL
monocyte	NULL
preparations	NULL
.	NULL
``	NULL

Our	NULL
failure	NULL
to	NULL
detect	NULL
constitutive	NULL
phosphorylation	NULL
of	NULL
either	NULL
STAT1	NULL
or	NULL
STAT3	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-10	NULL
suggests	NULL
that	NULL
B-CLL	NULL
cells	NULL
,	NULL
like	NULL
normal	NULL
B	NULL
cells	NULL
,	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
dependent	NULL
on	NULL
IL-10	NULL
for	NULL
IL-10	NULL
receptor	NULL
signaling	NULL
.	NULL

Whether	NULL
the	NULL
IL-10	NULL
receptor	NULL
on	NULL
B-CLL	NULL
cells	NULL
is	NULL
constitutively	NULL
occupied	NULL
and	NULL
activated	NULL
in	NULL
vivo	NULL
remains	NULL
to	NULL
be	NULL
investigated	NULL
.	NULL

It	NULL
was	NULL
also	NULL
of	NULL
interest	NULL
to	NULL
see	NULL
that	NULL
,	NULL
at	NULL
least	NULL
in	NULL
the	NULL
six	NULL
B-CLL	NULL
samples	NULL
tested	NULL
,	NULL
exogenous	NULL
IL-2	NULL
was	NULL
unable	NULL
to	NULL
induce	NULL
an	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
with	NULL
the	NULL
TB-2	NULL
probe	NULL
that	NULL
binds	NULL
STATS	NULL
.	NULL
``	NULL

IL-2	NULL
receptor	NULL
expression	NULL
has	NULL
been	NULL
documented	NULL
in	NULL
B-CLL	NULL
,	NULL
as	NULL
has	NULL
functional	NULL
responsiveness	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-2	NULL
.	NULL

``	NULL
``	NULL
``	NULL
*	NULL
``	NULL
Whether	NULL
the	NULL
absence	NULL
of	NULL
STATS	NULL
phosphorylation	NULL
following	NULL
IL-2	NULL
receptor	NULL
activation	NULL
will	NULL
be	NULL
a	NULL
consistent	NULL
finding	NULL
in	NULL
B-CLL	NULL
is	NULL
unknown	NULL
,	NULL
but	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
alternate	NULL
intracellular	NULL
signal	NULL
transduction	NULL
may	NULL
account	NULL
for	NULL
the	NULL
effects	NULL
of	NULL
IL-2	NULL
on	NULL
B-CLL	NULL
cells	NULL
.	NULL
``	NULL

As	NULL
IL-2	NULL
induces	NULL
STATS	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
,	NULL
``	NULL
this	NULL
finding	NULL
makes	NULL
it	NULL
unlikely	NULL
that	NULL
contaminating	NULL
T	NULL
cells	NULL
significantly	NULL
contributed	NULL
to	NULL
STAT1	NULL
and	NULL
STAT3	NULL
activation	NULL
in	NULL
our	NULL
studies	NULL
.	NULL

A	NULL
number	NULL
of	NULL
reports	NULL
have	NULL
documented	NULL
the	NULL
role	NULL
of	NULL
IL-10	NULL
as	NULL
a	NULL
survival	NULL
factor	NULL
for	NULL
human	NULL
B-cells	NULL
.	NULL

Levy	NULL
and	NULL
Brouet	NULL
``	NULL
showed	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
can	NULL
be	NULL
maintained	NULL
in	NULL
serum	NULL
free	NULL
medium	NULL
supplemented	NULL
with	NULL
IL-10	NULL
,	NULL
which	NULL
also	NULL
enhanced	NULL
bel-2	NULL
expression	NULL
.	NULL

Baiocchi	NULL
et	NULL
al	NULL
``	NULL
``	NULL
have	NULL
shown	NULL
that	NULL
IL-10	NULL
maintains	NULL
survival	NULL
of	NULL
EBV*	NULL
human	NULL
B	NULL
cells	NULL
in	NULL
serum	NULL
free	NULL
medium	NULL
via	NULL
a	NULL
bel-2-independent	NULL
mechanism	NULL
.	NULL

However	NULL
,	NULL
Fluckiger	NULL
et	NULL
al	NULL
``	NULL
``	NULL
reported	NULL
that	NULL
IL-10	NULL
could	NULL
induce	NULL
apoptosis	NULL
in	NULL
B-CLL	NULL
cells	NULL
.	NULL

In	NULL
that	NULL
study	NULL
,	NULL
blood	NULL
was	NULL
processed	NULL
in	NULL
vitro	NULL
with	NULL
E	NULL
rosetting	NULL
,	NULL
MoAbs	NULL
,	NULL
and	NULL
immunomagnetic	NULL
bead	NULL
deple-tions	NULL
before	NULL
culture	NULL
in	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

It	NULL
was	NULL
not	NULL
stated	NULL
if	NULL
survival	NULL
studies	NULL
were	NULL
performed	NULL
with	NULL
patient	NULL
material	NULL
that	NULL
was	NULL
fresh	NULL
or	NULL
frozen	NULL
,	NULL
but	NULL
in	NULL
our	NULL
experience	NULL
,	NULL
frozen	NULL
B-CLL	NULL
cells	NULL
display	NULL
a	NULL
substantial	NULL
reduction	NULL
in	NULL
IL-10	NULL
binding	NULL
specificity	NULL
compared	NULL
with	NULL
fresh	NULL
cells	NULL
(	NULL
J.	NULL
Tan	NULL
,	NULL
unpublished	NULL
observations	NULL
,	NULL
March	NULL
1995	NULL
)	NULL
.	NULL

Our	NULL
survival	NULL
studies	NULL
were	NULL
performed	NULL
on	NULL
both	NULL
fresh	NULL
blood	NULL
obtained	NULL
from	NULL
12	NULL
consecutive	NULL
B-CLL	NULL
patients	NULL
without	NULL
further	NULL
separation	NULL
of	NULL
cellular	NULL
components	NULL
,	NULL
as	NULL
well	NULL
as	NULL
seven	NULL
fresh	NULL
,	NULL
consecutive	NULL
patients	NULL
'	NULL
mononuclear	NULL
cells	NULL
cultured	NULL
in	NULL
medium	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

The	NULL
differences	NULL
in	NULL
cell	NULL
selection	NULL
and	NULL
cryopreservation	NULL
alone	NULL
could	NULL
account	NULL
for	NULL
the	NULL
discrepancy	NULL
in	NULL
our	NULL
results	NULL
and	NULL
those	NULL
of	NULL
Fluckiger	NULL
et	NULL
al	NULL
.	NULL

The	NULL
IL-10	NULL
receptor	NULL
belongs	NULL
to	NULL
the	NULL
same	NULL
family	NULL
as	NULL
the	NULL
IFN-a	NULL
and	NULL
IFN-y	NULL
receptors	NULL
.	NULL
``	NULL

All	NULL
three	NULL
members	NULL
of	NULL
this	NULL
cytokine	NULL
receptor	NULL
family	NULL
can	NULL
phosphorylate	NULL
STAT1	NULL
,	NULL
and	NULL
receptors	NULL
for	NULL
IL-10	NULL
and	NULL
IFN-a	NULL
@	NULL
can	NULL
also	NULL
phosphorylate	NULL
STAT3	NULL
,	NULL
in	NULL
normal	NULL
and	NULL
B-CLL	NULL
cells	NULL
.	NULL
``	NULL

IFN-a	NULL
and	NULL
IFN-y	NULL
have	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
enhance	NULL
B-CLL	NULL
differentiation	NULL
.	NULL
``	NULL

''	NULL
IFN-	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
inhibit	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
-	NULL
and	NULL
phytohemag-glutinin	NULL
(	NULL
PHA	NULL
)	NULL
-induced	NULL
proliferation	NULL
in	NULL
IFN-responsive	NULL
B-CLL	NULL
cells	NULL
.	NULL
``	NULL

These	NULL
results	NULL
are	NULL
compatible	NULL
with	NULL
our	NULL
assessment	NULL
of	NULL
the	NULL
functional	NULL
consequences	NULL
of	NULL
IL-10	NULL
binding	NULL
to	NULL
its	NULL
receptor	NULL
on	NULL
B-CLL	NULL
cells	NULL
and	NULL
also	NULL
with	NULL
the	NULL
previously	NULL
reported	NULL
IL-10-induced	NULL
differentiation	NULL
of	NULL
CD4O-activated	NULL
B-CLL	NULL
cells	NULL
.	NULL
``	NULL

Furthermore	NULL
,	NULL
IFN-a	NULL
@	NULL
and	NULL
,	NULL
as	NULL
confirmed	NULL
in	NULL
this	NULL
report	NULL
,	NULL
IFN-y	NULL
inhibit	NULL
apoptosis	NULL
in	NULL
B-CLL	NULL
cells	NULL
.	NULL
``	NULL

Although	NULL
IL-10	NULL
was	NULL
reported	NULL
to	NULL
induce	NULL
apoptosis	NULL
in	NULL
four	NULL
of	NULL
12	NULL
B-CLL	NULL
samples	NULL
,	NULL
``	NULL
another	NULL
report	NULL
by	NULL
the	NULL
same	NULL
group	NULL
demonstrated	NULL
4151	NULL
that	NULL
IL-10	NULL
enhanced	NULL
viable	NULL
B-cell	NULL
recovery	NULL
when	NULL
added	NULL
to	NULL
anti-CD40	NULL
activated	NULL
B-CLL	NULL
cells	NULL
without	NULL
and	NULL
with	NULL
IL-2	NULL
.	NULL
``	NULL

We	NULL
could	NULL
not	NULL
demonstrate	NULL
that	NULL
IL-10	NULL
induced	NULL
apoptosis	NULL
of	NULL
B-CLL	NULL
cells	NULL
.	NULL

Rather	NULL
,	NULL
IL-10	NULL
influenced	NULL
apoptosis	NULL
in	NULL
a	NULL
manner	NULL
opposite	NULL
to	NULL
that	NULL
of	NULL
HC	NULL
and	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
IFN-y	NULL
.	NULL

We	NULL
,	NULL
therefore	NULL
,	NULL
conclude	NULL
that	NULL
activation	NULL
of	NULL
the	NULL
IFN	NULL
family	NULL
of	NULL
receptors	NULL
on	NULL
B-CLL	NULL
cells	NULL
elicit	NULL
comparable	NULL
functional	NULL
re-sponses	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
each	NULL
factor	NULL
was	NULL
able	NULL
to	NULL
significantly	NULL
inhibit	NULL
HC-induced	NULL
apoptosis	NULL
as	NULL
observed	NULL
in	NULL
the	NULL
current	NULL
study	NULL
is	NULL
unknown	NULL
,	NULL
but	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
involve	NULL
an	NULL
isolated	NULL
alteration	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
bel-2	NULL
.	NULL

Whether	NULL
IL-10	NULL
receptor	NULL
activation	NULL
leads	NULL
to	NULL
alterations	NULL
in	NULL
other	NULL
members	NULL
of	NULL
the	NULL
bel-2	NULL
family	NULL
of	NULL
polypeptides	NULL
that	NULL
promote	NULL
or	NULL
inhibit	NULL
apoptosis	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

If	NULL
phosphorylation	NULL
of	NULL
STAT	NULL
proteins	NULL
proves	NULL
to	NULL
be	NULL
critical	NULL
to	NULL
this	NULL
process	NULL
,	NULL
as	NULL
has	NULL
recently	NULL
been	NULL
reported	NULL
for	NULL
pro-B	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
then	NULL
targeting	NULL
these	NULL
molecules	NULL
might	NULL
offer	NULL
novel	NULL
therapeutic	NULL
targets	NULL
for	NULL
chemo-resistant	NULL
B-CLL	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Glucksmann	NULL
A	NULL
:	NULL
Cell	NULL
deaths	NULL
in	NULL
normal	NULL
vertebrate	NULL
ontogeny	NULL
.	NULL

Biol	NULL
Rev	NULL
26:59	NULL
,	NULL
1951	NULL
2	NULL
.	NULL

Saunders	NULL
JWJ	NULL
:	NULL
Death	NULL
in	NULL
embryonic	NULL
systems	NULL
.	NULL

Science	NULL
154:604	NULL
,	NULL
1966	NULL
3	NULL
.	NULL

Andreeff	NULL
M	NULL
,	NULL
Darzynkiewicz	NULL
Z	NULL
,	NULL
Sharpless	NULL
TK	NULL
,	NULL
Clarkson	NULL
BD	NULL
,	NULL
Melamed	NULL
MR	NULL
:	NULL
Discrimination	NULL
of	NULL
human	NULL
leukemia	NULL
subtypes	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
cellular	NULL
DNA	NULL
and	NULL
RNA	NULL
.	NULL

Blood	NULL
55:282	NULL
,	NULL
1980	NULL
4	NULL
.	NULL

Dameshek	NULL
W	NULL
:	NULL
Chronic	NULL
lymphocytic	NULL
leukemia-an	NULL
accumulative	NULL
disease	NULL
of	NULL
immunolgically	NULL
incompetent	NULL
lymphocytes	NULL
.	NULL

Blood	NULL
29:566	NULL
,	NULL
1967	NULL
5	NULL
.	NULL

Rozman	NULL
C	NULL
,	NULL
Montserrat	NULL
E	NULL
:	NULL
Chronic	NULL
lymphocytic	NULL
leukemia	NULL
.	NULL

N	NULL
Engl	NULL
J	NULL
Med	NULL
333:1052	NULL
,	NULL
1995	NULL
6	NULL
.	NULL

Korsmeyer	NULL
SJ	NULL
,	NULL
Shutter	NULL
JR	NULL
,	NULL
Veis	NULL
DJ	NULL
,	NULL
Merry	NULL
DE	NULL
,	NULL
Oltvai	NULL
ZN	NULL
:	NULL
Bcl-2/Bax	NULL
:	NULL
A	NULL
rheostat	NULL
that	NULL
regulates	NULL
an	NULL
anti-oxidant	NULL
pathway	NULL
and	NULL
cell	NULL
death	NULL
.	NULL

Sem	NULL
Cancer	NULL
Biol	NULL
4:327	NULL
,	NULL
1993	NULL
7	NULL
.	NULL

McConkey	NULL
DJ	NULL
,	NULL
Chandra	NULL
J	NULL
,	NULL
Wright	NULL
S	NULL
,	NULL
Plunkett	NULL
W	NULL
,	NULL
McDonnell	NULL
TJ	NULL
,	NULL
Reed	NULL
J	NULL
C	NULL
,	NULL
Keating	NULL
M	NULL
:	NULL
Apoptosis	NULL
sensitivity	NULL
in	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
is	NULL
determined	NULL
by	NULL
endogenous	NULL
endonuclease	NULL
content	NULL
and	NULL
relative	NULL
expression	NULL
of	NULL
BCL-2	NULL
and	NULL
BAX	NULL
.	NULL

J	NULL
Immunol	NULL
156:2624	NULL
,	NULL
1996	NULL
8	NULL
.	NULL

Collins	NULL
RJ	NULL
,	NULL
Verschuer	NULL
LA	NULL
,	NULL
Harmon	NULL
BV	NULL
,	NULL
Prentice	NULL
RL	NULL
,	NULL
Pope	NULL
JH	NULL
,	NULL
Kerr	NULL
JF	NULL
:	NULL
Spontaneous	NULL
programmed	NULL
death	NULL
(	NULL
apoptosis	NULL
)	NULL
of	NULL
B-chronic	NULL
lymphocytic	NULL
leukaemia	NULL
cells	NULL
following	NULL
their	NULL
culture	NULL
in	NULL
vitro	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
71:343	NULL
,	NULL
1989	NULL
9	NULL
.	NULL

Dancescu	NULL
M	NULL
,	NULL
Rubio-Trujillo	NULL
M	NULL
,	NULL
Biron	NULL
G	NULL
,	NULL
Bron	NULL
D	NULL
,	NULL
Delespesse	NULL
G	NULL
,	NULL
Sarfati	NULL
M	NULL
:	NULL
Interleukin	NULL
4	NULL
protects	NULL
chronic	NULL
lymphocytic	NULL
leukemic	NULL
B	NULL
cells	NULL
from	NULL
death	NULL
by	NULL
apoptosis	NULL
and	NULL
upregulates	NULL
Bel-2	NULL
expression	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
176:1319	NULL
,	NULL
1992	NULL
10	NULL
.	NULL

Chaouchi	NULL
N	NULL
,	NULL
Wallon	NULL
C	NULL
,	NULL
Goujard	NULL
C	NULL
,	NULL
Tertian	NULL
G	NULL
,	NULL
Rudent	NULL
A	NULL
,	NULL
Caput	NULL
D	NULL
,	NULL
Ferrera	NULL
P	NULL
,	NULL
Minty	NULL
A	NULL
,	NULL
Vazquez	NULL
A	NULL
,	NULL
Delfraissy	NULL
JF	NULL
:	NULL
Interleukin-13	NULL
inhibits	NULL
interleukin-2-induced	NULL
proliferation	NULL
and	NULL
protects	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
B	NULL
cells	NULL
from	NULL
in	NULL
vitro	NULL
apoptosis	NULL
.	NULL

Blood	NULL
87:1022	NULL
,	NULL
1996	NULL
11	NULL
.	NULL

Buschle	NULL
M	NULL
,	NULL
Campana	NULL
D	NULL
,	NULL
Carding	NULL
SR	NULL
,	NULL
Richard	NULL
C	NULL
,	NULL
Hoffbrand	NULL
AV	NULL
,	NULL
Brenner	NULL
MK	NULL
:	NULL
Interferon	NULL
gamma	NULL
inhibits	NULL
apoptotic	NULL
cell	NULL
death	NULL
in	NULL
B	NULL
cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
177:213	NULL
,	NULL
1993	NULL
12	NULL
.	NULL

Jewell	NULL
AP	NULL
,	NULL
Worman	NULL
CP	NULL
,	NULL
Lydyard	NULL
PM	NULL
,	NULL
Yong	NULL
KL	NULL
,	NULL
Giles	NULL
FJ	NULL
,	NULL
Goldstone	NULL
AH	NULL
:	NULL
Interferon-alpha	NULL
up-regulates	NULL
bel-2	NULL
expression	NULL
and	NULL
protects	NULL
B-CLL	NULL
cells	NULL
from	NULL
apoptosis	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
88:268	NULL
,	NULL
1994	NULL
13	NULL
.	NULL

Fiorentino	NULL
DF	NULL
,	NULL
Bond	NULL
MW	NULL
,	NULL
Mosmann	NULL
TR	NULL
:	NULL
Two	NULL
types	NULL
of	NULL
mouse	NULL
T	NULL
helper	NULL
cell	NULL
.	NULL

IV	NULL
.	NULL

Th2	NULL
clones	NULL
secrete	NULL
a	NULL
factor	NULL
that	NULL
inhibits	NULL
cytokine	NULL
production	NULL
by	NULL
Th1	NULL
clones	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
170:2081	NULL
,	NULL
1989	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

4152	NULL
14	NULL
.	NULL

Fiorentino	NULL
DF	NULL
,	NULL
Zlotnik	NULL
A	NULL
,	NULL
Vieira	NULL
P	NULL
,	NULL
Mosmann	NULL
TR	NULL
,	NULL
Howard	NULL
M	NULL
,	NULL
Moore	NULL
KW	NULL
,	NULL
O'Garra	NULL
A	NULL
:	NULL
IL-10	NULL
acts	NULL
on	NULL
the	NULL
antigen-presenting	NULL
cell	NULL
to	NULL
inhibit	NULL
cytokine	NULL
production	NULL
by	NULL
Th1	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
146:3444	NULL
,	NULL
1991	NULL
15	NULL
.	NULL

Levy	NULL
Y	NULL
,	NULL
Brouet	NULL
JC	NULL
:	NULL
Interleukin-10	NULL
prevents	NULL
spontaneous	NULL
death	NULL
of	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
by	NULL
induction	NULL
of	NULL
the	NULL
bel-2	NULL
protein	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
93:424	NULL
,	NULL
1994	NULL
16	NULL
.	NULL

Baiocchi	NULL
RA	NULL
,	NULL
Ross	NULL
ME	NULL
,	NULL
Tan	NULL
JC	NULL
,	NULL
Chou	NULL
CC	NULL
,	NULL
Sullivan	NULL
L	NULL
,	NULL
Haldar	NULL
S	NULL
,	NULL
Monne	NULL
M	NULL
,	NULL
Seiden	NULL
MV	NULL
,	NULL
Narula	NULL
SK	NULL
,	NULL
Sklar	NULL
J	NULL
,	NULL
Croce	NULL
CM	NULL
,	NULL
Caligiuri	NULL
MA	NULL
:	NULL
Lymphomagenesis	NULL
in	NULL
the	NULL
SCID-hu	NULL
mouse	NULL
involves	NULL
abundant	NULL
production	NULL
of	NULL
human	NULL
interleukin-10	NULL
.	NULL

Blood	NULL
85:1063	NULL
,	NULL
1995	NULL
17	NULL
.	NULL

Fluckiger	NULL
AC	NULL
,	NULL
Durand	NULL
I	NULL
,	NULL
Banchereau	NULL
J	NULL
:	NULL
Interleukin	NULL
10	NULL
induces	NULL
apoptotic	NULL
cell	NULL
death	NULL
of	NULL
B-chronic	NULL
lymphocytic	NULL
leukemia	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
179:91	NULL
,	NULL
1994	NULL
18	NULL
.	NULL

Knauf	NULL
WU	NULL
,	NULL
Ehlers	NULL
B	NULL
,	NULL
Bisson	NULL
S	NULL
,	NULL
Thiel	NULL
E	NULL
:	NULL
Serum	NULL
levels	NULL
of	NULL
interleukin-10	NULL
in	NULL
B-cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
88:4382	NULL
,	NULL
1995	NULL
19	NULL
.	NULL

Egle	NULL
A	NULL
,	NULL
Marshitz	NULL
I	NULL
,	NULL
Posch	NULL
B	NULL
,	NULL
Herold	NULL
M	NULL
,	NULL
Greil	NULL
R	NULL
:	NULL
IL-10	NULL
serum	NULL
levels	NULL
in	NULL
B-cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
94:211	NULL
,	NULL
1996	NULL
20	NULL
.	NULL

Newman	NULL
RA	NULL
,	NULL
Peterson	NULL
B	NULL
,	NULL
Davey	NULL
FR	NULL
,	NULL
Brabyn	NULL
C	NULL
,	NULL
Collins	NULL
H	NULL
,	NULL
Brunetto	NULL
VL	NULL
,	NULL
Duggan	NULL
DB	NULL
,	NULL
Weiss	NULL
RB	NULL
,	NULL
Royston	NULL
I	NULL
,	NULL
Millard	NULL
FE	NULL
,	NULL
Miller	NULL
AA	NULL
,	NULL
Bloomfield	NULL
CD	NULL
:	NULL
Phenotypic	NULL
markers	NULL
and	NULL
BCL-1	NULL
gene	NULL
rearrangements	NULL
in	NULL
B-cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
:	NULL
A	NULL
Cancer	NULL
and	NULL
Leukemia	NULL
Group	NULL
B	NULL
study	NULL
.	NULL

Blood	NULL
82:1239	NULL
,	NULL
1993	NULL
21	NULL
.	NULL

Tan	NULL
JC	NULL
,	NULL
Indelicato	NULL
SR	NULL
,	NULL
Narula	NULL
SK	NULL
,	NULL
Zavodny	NULL
PJ	NULL
,	NULL
Chou	NULL
CC	NULL
:	NULL
Characterization	NULL
of	NULL
interleukin-10	NULL
receptors	NULL
on	NULL
human	NULL
and	NULL
mouse	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
268:21053	NULL
,	NULL
1993	NULL
22	NULL
.	NULL

Sadowski	NULL
HB	NULL
,	NULL
Shuai	NULL
K	NULL
,	NULL
Darnell	NULL
JE	NULL
,	NULL
Jr	NULL
,	NULL
Gilman	NULL
MZ	NULL
:	NULL
A	NULL
common	NULL
nuclear	NULL
signal	NULL
transduction	NULL
pathway	NULL
activated	NULL
by	NULL
growth	NULL
factor	NULL
and	NULL
cytokine	NULL
receptors	NULL
.	NULL

Science	NULL
261:1739	NULL
,	NULL
1993	NULL
23	NULL
.	NULL

Wang	NULL
Y	NULL
,	NULL
Morella	NULL
KK	NULL
,	NULL
Ripperger	NULL
J	NULL
,	NULL
Lai	NULL
CF	NULL
,	NULL
Gearing	NULL
DP	NULL
,	NULL
Fey	NULL
GH	NULL
,	NULL
Campos	NULL
SP	NULL
,	NULL
Baumann	NULL
H	NULL
:	NULL
Receptors	NULL
for	NULL
interleukin-3	NULL
(	NULL
IL-3	NULL
)	NULL
and	NULL
growth	NULL
hormone	NULL
mediate	NULL
an	NULL
IL-6-type	NULL
transcriptional	NULL
induction	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
JAK2	NULL
or	NULL
STAT3	NULL
.	NULL

Blood	NULL
86:1671	NULL
,	NULL
1995	NULL
24	NULL
.	NULL

Jurlander	NULL
J	NULL
,	NULL
de	NULL
Nully	NULL
Brown	NULL
P	NULL
,	NULL
Skov	NULL
PS	NULL
,	NULL
Henrichsen	NULL
J	NULL
,	NULL
Heron	NULL
I	NULL
,	NULL
Obel	NULL
N	NULL
,	NULL
Mortensen	NULL
BT	NULL
,	NULL
Hansen	NULL
MM	NULL
,	NULL
Geisler	NULL
CH	NULL
,	NULL
Nielsen	NULL
HJ	NULL
:	NULL
Improved	NULL
vaccination	NULL
response	NULL
during	NULL
ranitidine	NULL
treatment	NULL
,	NULL
and	NULL
increased	NULL
plasma	NULL
histamine	NULL
concentrations	NULL
,	NULL
in	NULL
patients	NULL
with	NULL
B	NULL
cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
.	NULL

Leukemia	NULL
9:1902	NULL
,	NULL
1995	NULL
25	NULL
.	NULL

Nicoletti	NULL
I	NULL
,	NULL
Migliorati	NULL
G	NULL
,	NULL
Pagliacci	NULL
MC	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Riccardi	NULL
C	NULL
:	NULL
A	NULL
rapid	NULL
and	NULL
simple	NULL
method	NULL
for	NULL
measuring	NULL
thymocyte	NULL
apoptosis	NULL
by	NULL
propidium	NULL
iodide	NULL
staining	NULL
and	NULL
flow	NULL
cytometry	NULL
.	NULL

J	NULL
Immunol	NULL
Methods	NULL
139:271	NULL
,	NULL
1991	NULL
26	NULL
.	NULL

Finbloom	NULL
DS	NULL
,	NULL
Winestock	NULL
KD	NULL
:	NULL
IL-10	NULL
induces	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
tyk2	NULL
and	NULL
Jak1	NULL
and	NULL
the	NULL
differential	NULL
assembly	NULL
of	NULL
STAT1	NULL
alpha	NULL
and	NULL
STAT3	NULL
complexes	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
and	NULL
mono-cytes	NULL
.	NULL

J	NULL
Immunol	NULL
155:1079	NULL
,	NULL
1995	NULL
JURLANDER	NULL
ET	NULL
AL	NULL
27	NULL
.	NULL

Trentin	NULL
L	NULL
,	NULL
Zambello	NULL
R	NULL
,	NULL
Agostini	NULL
C	NULL
,	NULL
Enthammer	NULL
C	NULL
,	NULL
Cerutti	NULL
A	NULL
,	NULL
Adami	NULL
F	NULL
,	NULL
Zamboni	NULL
S	NULL
,	NULL
Semenzato	NULL
G	NULL
:	NULL
Expression	NULL
and	NULL
regulation	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
,	NULL
interleukin-2	NULL
,	NULL
and	NULL
hematopoietic	NULL
growth	NULL
factor	NULL
receptors	NULL
in	NULL
B-cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
84:4249	NULL
,	NULL
1994	NULL
28	NULL
.	NULL

Fluckiger	NULL
AC	NULL
,	NULL
Garrone	NULL
P	NULL
,	NULL
Durand	NULL
I	NULL
,	NULL
Galizzi	NULL
JP	NULL
,	NULL
Banchereau	NULL
J	NULL
:	NULL
Interleukin	NULL
10	NULL
(	NULL
IL-10	NULL
)	NULL
upregulates	NULL
functional	NULL
high	NULL
affinity	NULL
IL-2	NULL
receptors	NULL
on	NULL
normal	NULL
and	NULL
leukemic	NULL
B	NULL
lymphocytes	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
178:1473	NULL
,	NULL
1993	NULL
29	NULL
.	NULL

Panayiotidis	NULL
P	NULL
,	NULL
Ganeshaguru	NULL
K	NULL
,	NULL
Jabbar	NULL
SA	NULL
,	NULL
Hoffbrand	NULL
AV	NULL
:	NULL
Interleukin-4	NULL
inhibits	NULL
apoptotic	NULL
cell	NULL
death	NULL
and	NULL
loss	NULL
of	NULL
the	NULL
bel-2	NULL
protein	NULL
in	NULL
B-chronic	NULL
lymphocytic	NULL
leukaemia	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
85:439	NULL
,	NULL
1993	NULL
30	NULL
.	NULL

Carson	NULL
WE	NULL
,	NULL
Lindemann	NULL
MJ	NULL
,	NULL
Baiocchi	NULL
R	NULL
,	NULL
Linett	NULL
M	NULL
,	NULL
Tan	NULL
JC	NULL
,	NULL
Chou	NULL
CC	NULL
,	NULL
Narula	NULL
S	NULL
,	NULL
Caligiuri	NULL
MA	NULL
:	NULL
The	NULL
functional	NULL
characterization	NULL
of	NULL
interleukin-10	NULL
receptor	NULL
expression	NULL
on	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
.	NULL

Blood	NULL
85:3577	NULL
,	NULL
1995	NULL
31	NULL
.	NULL

Brechner	NULL
T	NULL
,	NULL
Hocke	NULL
G	NULL
,	NULL
Goel	NULL
A	NULL
,	NULL
Fey	NULL
GH	NULL
:	NULL
Interleukin	NULL
6	NULL
response	NULL
factor	NULL
binds	NULL
co-operatively	NULL
at	NULL
two	NULL
adjacent	NULL
sites	NULL
in	NULL
the	NULL
promoter	NULL
upstream	NULL
region	NULL
of	NULL
the	NULL
rat	NULL
alpha	NULL
2-macroglobulin	NULL
gene	NULL
.	NULL

Mol	NULL
Bio	NULL
Med	NULL
8:267	NULL
,	NULL
1991	NULL
32	NULL
.	NULL

Tsilivakos	NULL
V	NULL
,	NULL
Tsapis	NULL
A	NULL
,	NULL
Kakolyris	NULL
S	NULL
,	NULL
Hliakis	NULL
P	NULL
,	NULL
Perraki	NULL
M	NULL
,	NULL
Georgoulias	NULL
V	NULL
:	NULL
Characterization	NULL
of	NULL
interleukin	NULL
2	NULL
receptors	NULL
on	NULL
B-cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
cells	NULL
.	NULL

Leukemia	NULL
8:1571	NULL
,	NULL
1994	NULL
33	NULL
.	NULL

Schindler	NULL
C	NULL
,	NULL
Dammell	NULL
JB	NULL
,	NULL
Jr	NULL
:	NULL
Transcriptional	NULL
responses	NULL
to	NULL
poly-peptide	NULL
ligands	NULL
:	NULL
the	NULL
JAK-STAT	NULL
pathway	NULL
.	NULL

Annu	NULL
Rev	NULL
Biochem	NULL
64:621	NULL
,	NULL
1995	NULL
34	NULL
.	NULL

Lai	NULL
CF	NULL
,	NULL
Ripperger	NULL
J	NULL
,	NULL
Morella	NULL
KK	NULL
,	NULL
Jurlander	NULL
J	NULL
,	NULL
Hawley	NULL
TS	NULL
,	NULL
Carson	NULL
WE	NULL
,	NULL
Kordula	NULL
T	NULL
,	NULL
Caligiuri	NULL
MA	NULL
,	NULL
Hawley	NULL
RG	NULL
,	NULL
Fey	NULL
GH	NULL
,	NULL
Baumann	NULL
H	NULL
:	NULL
Receptors	NULL
for	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-10	NULL
and	NULL
IL-6-type	NULL
cytokines	NULL
use	NULL
similar	NULL
signaling	NULL
mechanisms	NULL
for	NULL
inducing	NULL
transcription	NULL
through	NULL
IL-6	NULL
response	NULL
elements	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
271:13968	NULL
,	NULL
1996	NULL
35	NULL
.	NULL

Xu	NULL
B	NULL
,	NULL
Grander	NULL
D	NULL
,	NULL
Sangfelt	NULL
O	NULL
,	NULL
Einhorn	NULL
S	NULL
:	NULL
Primary	NULL
leukemia	NULL
cells	NULL
resistant	NULL
to	NULL
alpha-interferon	NULL
in	NULL
vitro	NULL
are	NULL
defective	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
DNA-binding	NULL
factor	NULL
interferon-stimulated	NULL
gene	NULL
factor	NULL
3	NULL
.	NULL

Blood	NULL
84:1942	NULL
,	NULL
1994	NULL
36	NULL
.	NULL

Totterman	NULL
TH	NULL
,	NULL
Danersund	NULL
A	NULL
,	NULL
Carlsson	NULL
M	NULL
,	NULL
Nilsson	NULL
K	NULL
:	NULL
Effects	NULL
of	NULL
recombinant	NULL
interferon-a	NULL
and	NULL
-y	NULL
on	NULL
B-CLL	NULL
cells	NULL
in	NULL
serum-free	NULL
medium	NULL
:	NULL
Expression	NULL
of	NULL
activation	NULL
,	NULL
differentiation	NULL
and	NULL
CALLA	NULL
anti-gens	NULL
.	NULL

Leukemia	NULL
9:667	NULL
,	NULL
1987	NULL
37	NULL
.	NULL

Ostlund	NULL
L	NULL
,	NULL
Einhorn	NULL
S	NULL
,	NULL
Robert	NULL
K-H	NULL
,	NULL
Julisson	NULL
G	NULL
,	NULL
Biberfeld	NULL
P	NULL
:	NULL
Chronic	NULL
B-lymphocytic	NULL
leukemia	NULL
cells	NULL
proliferate	NULL
and	NULL
differentiate	NULL
following	NULL
exposure	NULL
to	NULL
interferon	NULL
in	NULL
vitro	NULL
.	NULL

Blood	NULL
67:152	NULL
,	NULL
1986	NULL
38	NULL
.	NULL

Fukada	NULL
T	NULL
,	NULL
Hibi	NULL
M	NULL
,	NULL
Yamanaka	NULL
Y	NULL
,	NULL
Takahashi-Tezuka	NULL
M	NULL
,	NULL
Fuji-tani	NULL
Y	NULL
,	NULL
Yamaguchi	NULL
T	NULL
,	NULL
Nakajima	NULL
K	NULL
,	NULL
Hirano	NULL
T	NULL
:	NULL
Two	NULL
signals	NULL
are	NULL
necessary	NULL
for	NULL
cell	NULL
proliferation	NULL
induced	NULL
by	NULL
a	NULL
cytokine	NULL
receptor	NULL
gp130	NULL
:	NULL
Involvement	NULL
of	NULL
STAT3	NULL
in	NULL
anti-apoptosis	NULL
.	NULL

Immunity	NULL
5:449	NULL
,	NULL
1996	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blO	NULL
0d	NULL
1997	NULL
89	NULL
:	NULL
4146-4152	NULL
Characterization	NULL
of	NULL
Interleukin-10	NULL
Receptor	NULL
Expression	NULL
on	NULL
B-Cell	NULL
Chronic	NULL
Lymphocytic	NULL
Leukemia	NULL
Cells	NULL
4	NULL
VIN	NULL
“	NULL
CA	NULL
VJ-	NULL
,	NULL
'	NULL
\se	NULL
@	NULL
.	NULL

2	NULL
YOtow®	NULL
@	NULL
207	NULL
Jesper	NULL
Jurlander	NULL
,	NULL
Chun-Fai	NULL
Lai	NULL
,	NULL
Jimmy	NULL
Tan	NULL
,	NULL
Chuan-Chu	NULL
Chou	NULL
,	NULL
Christian	NULL
H.	NULL
Geisler	NULL
,	NULL
Jeffrey	NULL
Schriber	NULL
,	NULL
Leslie	NULL
E.	NULL
Blumenson	NULL
,	NULL
Satwant	NULL
K.	NULL
Narula	NULL
,	NULL
Heinz	NULL
Baumann	NULL
and	NULL
Michael	NULL
A.	NULL
Caligiuri	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/89/11/4146.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Neoplasia	NULL
(	NULL
4182	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

